Author index to Volume 43

Aakerlund L, Hemmingsen R. Neural networks as models of psychopathology, 471
Adebogun O. See Amin F
Adès J. See Bruins-Slot L
Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers, 811
Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J. Long-term treatment effects of vitamin E for tardive dyskinesia, 868
Adler LE. See Freedman R
Aitchison KJ. See Holmes C
Alexander GE. See Krasuski JS
Allard P. See Spigset O
Alpert J. See Mooney JJ
Altshuler L. See Parekh PI
Amador X. See Malaspina D
Amaya-Jackson L. See Strober M
Amenedo E, Díaz F. Effects of Aging on middle-latency auditory evoked potentials: a cross-sectional study, 210
Amin F, Hashmi A, Stroe AE, Adebogun O, Densmore D, Knott PJ. Reproducibility of plasma catecholamine metabolites in normal subjects, 233
Andia I, Zumarraga M, Zabalo MJ, Bulbena A, Davila R. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia, 20
Antonarakis SE. See Karayiorgou M
Arakaki H. See Hirayasu Y
Arana GW. See Labbate LA
Arranz MJ. See Gutiérrez B
Arvat E. See Gianotti L
Asato N. See Hirayasu Y
Askenazy F, Candito M, Caci H, Myquel M, Chambon P, Darcourt G, Puech AJ. Whole blood serotonin content, tryptophan concentrations, and impulsivity in anorexia nervosa, 188
Assmus JD. See Kripke DF

Bakshi VP, Swerdlow NR, Braff DL, Geyer MA. Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine, 436
Baldwin CM. See Bell IR
Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS, Costa DC, Ell PJ, Kerwin RW. Cognitive functioning and $GABA_a$/benzodiazepine receptor binding in schiziphrenia: a ^{123}I-iomazenil SPET study, 107
Ballenger JC. See Labbate LA
Barker C. See Wehr TA
Beasley CM. See Tollefson GD
Bell IR, Schwartz GE, Hardin EE, Baldwin CM, Kline JP. Differential resting quantitative electroencephalographic alpha patterns in women with environmental chemical intolerance, depressives, and normals, 376
Benazzi F. Sertraline discontinuation syndrome presenting with severe depression and compulsions, 929-corr
Benes F, Coyle JT. Déja vu all over again, 781-ed
Benjamin Y. See Manor I
Beoni AM. See Rocca P
Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients with Tourette's syndrome: a clinical study, 364
Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study, 641
Betranpetit J. See Gutiérrez B
Bhatti T, Gillin JC, Seifritz E, Moore P, Clark C, Golshan S, Stahl S, Rapaport M, Kelsoe J. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood, 52
Bischof R. See Hemmeter U
Bleichner F. See Rechlin T
Bloch M, Schmidt PJ, Su T-P, Tobin MB, Rubinow DR. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls, 897
Blot P. See Bruins-Slot L
Bocola V, Trecco MD, Fabbrini G, Paladini C, Sollecito A, Martucci N. Antipanic effect of fluoxetine measured by CO_2 challenge test, 612
Bouma A. See Scherder EJA
Boutros NN, Krupitsky EM. Cranial electrostimulation therapy, 468-corr
Bouvard M. See Bruins-Slot L
Bowers MB Jr, Malison RT, Seibyl JP, Kosten TR. Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal, 278
Braff DL
See Bakshi VP
See Cadenhead KS
See Light GA
Braff DL, Light GA. Selection of digital filtering parameters and P50 amplitude-resonse, 922
Brammer GL. See Moffitt TE
Brawman-Mintzer O
See Johnson MR
See Labbate LA
Breier A
See Adler CM
See Bertolino A
Brenner R. See Madhusoodanan S
Broocks A, Little JT, Martin A,

© 1998 Society of Biological Psychiatry

0006-3223/98/$19.00
PII S006-3223(97)00444

Minichiello MD, Dubbert B, Mack C, Tune L, Murphy DL, Sunderland T. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls, 408
Brooks WM, Hodde-Vargas J, Vargas LA, Yeo RA, Ford CC, Hendren RL. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance study, 263
Brown K, Red A, White T, Henderson T, Hukin S, Johnstone C, Glen A. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia, 863
Bruder G. See Malaspina D
Bruins-Slot L, Gorwood P, Bouvard M, Blot P, Adès J, Feingold J, Schwartz J-C, Mouren- Siméoni M-C. Lack of association between anorexia nervosa and D3 dopamine receptor gene, 76
Bruno R. See Servan-Schreiber D
Bubeck B. See Schröder J
Buchsbaum MS. See Davis KL
Buff D. See Madhusoodanan S
Bulbena A. See Andia I
Bundren JC. See Warnock JK
Bunney WE Jr. See Jin Y
Busatto GF. See Ball S

Caci H. See Askenazy F
Cadenhead KS, Serper Y, Braff DL. Transient versus sustained visual channels in the visual backward masking deficits of schizophrenia patients, 132
Callahan A. See Parekh PI
Callicott JH. See Bertolino A
Camanni F. See Gianotti L
Campos VM. See Berthier ML
Candito M. See Askenazy F
Cannon TD. See Zorrilla EP
Carlsson A. See Lahti AC
Carlström K. See Rasmuson S
Carpenter WT Jr, Magno Zito J, Vitrai J, Volavka J. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D_2 receptor occupancy?, 79
Carroll BJ. See Cassidy F
Carter C. See Servan-Schreiber D
Caspi A. See Moffitt TE
Cassano GB. See Johnson MR
Cassidy F, Murry E, Carroll BJ. Tryptophan depletion in recently manic patients treated with lithium, 230
Cassidy F, Ritchie JC, Carroll BJ. Plasma dexamethasone concentration and cortisol response during manic episodes, 747
Centorrino F. See Frankenburg FR
Chalmers DT. See López J
Chambon P. See Askenazy F
Chang KD, Keck PE Jr, Stanton SP, McElroy SL, Strakowski SM, Geracioti TD Jr. Differences in thyroid function between bipolar manic and mixed states, 730
Chang Y-S. See Hong C-J
Charney DS, Innis RB, Nestler EJ. New Leadership for *Biological Psychiatry*, 1-ed
Childs NL. See Stanislav SW
Chiu H-J. See Hong C-J
Clark C. See Bhatti T
Clark CP, Gillin JC, Golshan G, Demodena A, Smith TL, Danowski S, Irwin M, Schuckit M. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression, 601
Clark S. See Malaspina D
Clements A. See Young AH
Cohen J. See Servan-Schreiber D
Cohen-Kettenis PT. See van Goozen SHM
Colbath EA. See Turetsky BI
Colenda CC. See McCall WV
Collier DA
See Gutiérrez B
See Holmes C
Colodzin R. See Mooney JJ
Corey PK. See Lahti AC
Correnti EE. See Mahadik SP
Cosgrave M. See Tyrrell J
Costa DC. See Ball S
Cottencin O. See Thomas P
Cowen PJ. See Young AH
Coyle JT. See Benes F
Crawford M. See Labbate LA
Crayton JW. See Delisi SM
Crismon ML. See Stanislav SW
Cummings S. See Yaffe K

Daly EM. See Krasuski JS
Dan B. See Kornreich C
Danowski S. See Clark CP
Darcourt G. See Askenazy F
David AS. See Ball S
Davila R. See Andia I
Davis KL. See Silverman JM
Davis KL, Buchsbaum MS, Shihabuddin L, Spiegel-Cohen J, Metzger M, Frecska E, Keefe RS, Powchik P. Ventricular enlargement in poor-outcome schizophrenia, 783
DeAntonio M. See Strober M
Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy, 483
Delisi SM, Konopka LM, O'Connor FL, Crayton JW. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: relationship to symptomatology and medication, 327
Demisch S. See Schröder J
Demodena A. See Clark CP
Densmore D. See Amin F
Deuschle M, Schweiger U, Gotthardt U, Weber B, Körner A, Schmider J, Standhardt H, Lammers C-L, Krumm B, Heuser I. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test, 762
Devanand DP. See Lisanby SH
de Vos RAI. See Hoogendijk WJG
de Wied D. See van Londen L
Díaz F. See Amenedo E
Di Clementi JD. See Hamilos DL
Di Vito L. See Gianotti L

Dodig G. See Jelovac N
Dollfus S. See Thibaut F
Donnino R. See Portas CM
Dourmap N. See Thibaut F
Dowling B. See Young AH
Dramaix M. See Hubain PP
Dubbert B. See Broocks A
Dufeu P. See Sander T
Duncan E. See Adler LA
Dyck Flory J, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function, 320

Edson R. See Adler LA
Ekman R. See Westrin Å
Ell PJ. See Ball S
Ellis WG. See Murphy GM Jr
Ellman G. See Frederick SL
Elman I. See Bertolino A
Emmanuel N. See Labbate LA
Emmanuel NP. See Johnson MR
Eriksson S. See Rasmuson S
Escribá PV. See García-Sevilla JA
Ettinger B. See Yaffe K
Eva C. See Rocca P

Fabbrini G. See Bocola V
Fañanás L. See Gutiérrez B
Fant R. See Pickworth W
Faustman WO. See Lauriello J
Fawcett JP. See Moffitt TE
Fein D. See Modahl C
Fein G. See Deicken RF
Feingold J. See Bruins-Slot L
Feinstein C. See Modahl C
Fekkes D. See Verkes RJ
Fell RL. See Kripke DF
Ferrero P. See Rocca P
Fischer !. See Portas CM
Fitzsimons L. See Lisanby SH
Fleming K. See Jin Y
Fontaine E. See Kornreich C
Ford CC. See Brooks WM
Forno LS. See Murphy GM Jr
Frank C. See Röschke J
Frank JA. See Bertolino A
Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change, 520
Frankhuijzen-Sierevogel AC. See van Londen L
Frecska E. See Davis KL
Frederick SL, Reus VI, Ginsberg D, Hall SM, Munoz RF, Ellman G. Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers, 525
Freed WJ. See van Kammen DP
Freedman R, Adler LE, Nagamoto HT, Wald MC. Selection of digital filtering parameters and P50 amplitude, 921
Frye MA. See Parekh PI
Fujikawa DG. See Swarztrauber K
Fukuzako H, Kodama S. Captum septum pellucidum in schizophrenia, 467-corr

Galke BL. See Karayiorgou M
Gangadhar BN. See Rajan I
García-Sevilla JA, Escribá PV, Ozaita A, Walzer C, Guimón J. Density of imidazoline receptors in platelets of euthymic patients with bipolar affective disorder and in brains of lithium-treated rats, 616
Garfinkel L. See Kripke DF
Geider FJ. See Schröder J
Geracioti TD Jr. See Chang KD
Gershtenson J. See Hamilos DL
Geyer MA. See Bakshi VP
Ghigo E. See Gianotti L
Gianotti L, Arvat E, Valetto MR, Ramunni J, Di Vito L, Maccagno B, Camanni F, Ghigo E. Effects of beta- adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa, 181
Gill M. See Tyrrell J
Gillin JC
See Bhatti T
See Clark CP
Ginsberg D. See Frederick SL
Gispen-de Wied C. See van Goozen SHM
Glen A. See Brown K
Goekoop JG. See van Londen L
Goetz R. See Malaspina D
Goffman A. See Pickworth W
Gogos JA. See Karayiorgou M
Goldberg TE. See Adler CM
Goldstein JM. See Portas CM
Golshan G. See Clark CP
Golshan S. See Bhatti T
Gönül AS. See Tutus A
Good KP. See Kopala LC
Gorman J. See Malaspina D
Gorwood P. See Bruins-Slot L
Goto T. See Tsuneoka Y
Gotthardt U. See Deuschle M
Goudemand M. See Thomas P
Grabarević Ž. See Jelovac N
Green L. See Modahl C
Grimes JB. See Labbate LA
Guillamat R. See Gutiérrez B
Guimón J. See García-Sevilla JA
Guo SL. See Silverman JM
Gur RC. See Kohler C
Gur RE
See Kohler C
See Turetsky BI
See Zorrilla EP
Gurklis JA. See van Kammen DP
Gutiérrez B, Arranz MJ, Collier DA, Vallès V, Guillamat R, Betranpetit J, Murray RM, Fañanás L. Serotonin transporter gene and risk for bipolar affective disorder: an association study in a Spanish population, 843

Hall SM. See Frederick SL
Halme M. See Lauerma H
Hamilos DL, Nutter D, Gershtenson J, Redmond DP, Di Clementi JD, Schmaling KB, Make BJ, Jones JF. Core body temperature is normal in chronic fatigue syndrome, 293
Hardin EE. See Bell IR
Harkavy Friedman J. See Malaspina D
Harms H. See Sander T
Harper Mozley L. See Kohler C
Hashimoto T. See Kitamura N
Hashmi A. See Amin F
Hatzinger M. See Hemmeter U
Hawi Z. See Tyrrell J
Hawton KE. See Young AH
Hemmeter U, Bischof R, Hatzinger M, Seifritz E, Holsboer-Trachsler E. Microsleep during partial sleep deprivation in depression, 829
Hemmingsen R. See Aakerlund L
Hemperly JJ. See van Kammen DP
Hemsley DR. See Ball S

Henderson T. See Brown K
Hendren RL. See Brooks WM
Hengeveld M. See Verkes RJ
Heninger GR. See Price LH
Henningfield J. See Pickworth W
Hermesh H. See Manor I
Hetrick WP. See Jin Y
Heuser I. See Deuschle M
Hill SY, Locke J, Zezza N, Kaplan B, Neiswanger K, Steinhauer SR, Wipprecht G, Xu J. Genetic association between reduced P300 amplitude an the DRD2 dopamine receptor A1 allele in children at high risk for alcoholism, 40
Hirayasu Y, Asato N, Ohta H, Hokama H, Arakaki H, Ogura C. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment, 244
Hodde-Vargas J. See Brooks WM
Hoehe M. See Sander T
Hoff AL. See Murphy GM Jr
Hofman MA. See Hoogendijk WJG
Hohagen F. See Schmidtke K
Hokama H
See Hirayasu Y
See Portas CM
Holmes C, Russ C, Kirov G, Aitchison KJ, Powell JF, Collier DA, Lovestone S. Apolipoprotein E: depressive illness, depressive symptoms, and Alzheimer's disease, 159
Holsboer F. See Ströhle A
Holsboer-Trachsler E. See Hemmeter U
Honer WG. See Kopala LC
Hong C-J, Chiu H-J, Chang Y-S, Sim C-B. Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients, 432
Hoogendijk WJG, Purba JS, Hofman MA, de Vos RAI, Jansen ENH, Swaab DF. Depression in Parkinson's disease is not accompanied by more corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus, 913
Horrobin D. See Peet M
Horwitz B. See Krasuski JS
Housman DE. See Karayiorgou M
Hubain PP. See Staner L
Hubain PP, Staner L, Dramaix M, Kerkhofs M, Papadimitriou G, Mendlewicz J, Linkowski P. The dexamethasone suppression test and sleep electroencephalogram in nonbipolar major depressed inpatients: a multivariate analysis, 220
Hukin S. See Brown K
Hyman Rapaport M. Circulating lymphocytic phenotypic surface markers in anxiety disorder patients and normal volunteers, 458

Ichinowatari N. See Tsuneoka Y
Innis RB. See Charney DS
Inoue K. See Inui K
Inui K, Motomura E, Okushima R, Kaige H, Inoue K, Nomura J. Electroencephalographic findings in patients with DSM-IV mood disorder, schizophrenia, and other psychotic disorders, 69
Irwin M. See Clark CP

Janakiramaiah N. See Rajan I
Jane J. See McCall WV
Jansen ENH. See Hoogendijk WJG
Jatlow P. See McCance-Katz EF
Jelovac N, Sikirić P, Rucĥman R, Petek M, Perović D, Konjevoda P, Marović A, Seiwerth S, Grabarević Ž, Sumajstorĉić J, Dodig G, Perić J. A novel pentadecapeptide, BPC 157, 511
Jin Y, Bunney WE Jr, Sandman CA, Patterson JV, Fleming K, Moenter JR, Kalali AH, Hetrick WP, Potkin SG. Is P50 suppression a measure of sensory gating in schizophrenia?, 873
Johnson EO. See van den Bree MBM
Johnson MR. See Labbate LA
Johnson MR, Marazitti D, Brawman-Mintzer O, Emmanuel NP, Ware MR, Morton WA, Rossi A, Cassano GB, Lydiard RB. Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia, 306
Johnstone C. See Brown K
Jolesz FA. See Portas CM
Jones JF. See Hamilos DL
Jones SH. See Ball S
Joraschky P. See Rechlin T

Kaige H. See Inui K
Kajimoto Y. See Kitamura N
Kalali AH. See Jin Y
Kando J. See Frankenburg FR
Kaplan B. See Hill SY
Kapp R. See Labbate LA
Karaasian F. See Tutus A
Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, Kazazian HH, Housman DE, Pulver AE. Identification of sequence variants and analysis of the role of catechol-*O*-methyltransferase gene in schizophrenia susceptibility, 425
Karr M. See Schröder J
Kaufmann C. See Malaspina D
Kazazian HH. See Karayiorgou M
Keck PE Jr. See Chang KD
Keefe RS. See Davis KL
Kelley ME. See van Kammen DP
Kellner M. See Ströhle A
Kelsoe J. See Bhatti T
Kerkhof AJFM. See Verkes RJ
Kerkhof GA. See van Londen L
Kerkhofs M. See Hubain PP
Kerwin RW. See Ball S
Keshavan MS. See Rosenberg DR
Kessler J. See Zorrilla EP
Ketter TA. See Parekh PI
Kikinis R. See Portas CM
Kim YK, Lee MS, Suh KY. Decreased interleukin-2 production in Korean schizophrenic patients, 701
Kinoshita T. See Saito N
Kirov G. See Holmes C
Kitamura N. See Yang C-Q
Kitamura N, Nishino N, Hashimoto T, Kajimoto Y, Shirai Y, Murakami N, Yang C-Q, Lin X-H, Yamamoto H, Nakai T, Mita T, Komure O, Shirakawa O, Nakai H. Assymetrical changes in the fodrin α subunit in the superior temporal cortices in schizophrenia, 254
Klauber MR. See Kripke DF
Kline JP. See Bell IR
Knott PJ. See Amin F

Kochi K. See Saito N
Koczapski AB. See Kopala LC
Kodama S. See Fukuzako H
Koenig T. See Saito N
Kohler C, Gur RC, Swanson CL, Petty R, Gur RE. Depression in schizophrenia: I. Association with neuropsychological deficits, 165
Kohler C, Swanson CL, Gur RC, Harper Mozley L, Gur RE. Depression in schizophrenia: II. MRI and PET findings, 173
Komure O. See Kitamura N
Konjevoda P. See Jelovac N
Konopka LM. See Delisi SM
Kopala LC, Good KP, Koczapski AB, Honer WG. Olfactory deficits in patients with schizophrenia and severe polydypsia, 497
Körner A. See Deuschle M
Kornreich C, Dan B, Verbanck P, Fontaine E, Pelc I. Divergent responses to fluoxetine from two compulsive, food-related conditions: bulimia nervosa and compulsive water drinking, 310
Kosten TR
See Bowers MB Jr
See McCance-Katz EF
Koutsos M. See Mooney JJ
Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DGM, Rapoport SI, Schapiro MB. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls), 60
Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics, 687
Krishnan KRR. See Steffens DC
Krumm B. See Deuschle M
Krupitsky EM. See Boutros NN
Kuginuki T. See Saito N
Kuğu N. See Tutus A
Kuhn S. See Sander T
Kulisevsky J. See Berthier ML
Kyrios M. See Purcell R

Labbate LA, Grimes JB, Arana GW. Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders, 904
Labbate LA, Johnson MR, Lydiard RB, Brawman-Mintzer O, Emmanuel N, Crawford M, Kapp R, Ballenger JC. Sleep deprivation in social phobia and generalized anxiety disorder, 840
Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (Preclamol) in schizophrenia, 2
Lahti RA. See Lahti AC
Lammers C-L. See Deuschle M
Latz S. See Strober M
Lauerma H, Wuorela M, Halme M. Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxy-methamphetamine?, 929-corr
Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL, Lim KO, Pfefferbaum A. Association between regional brain volumes and clozapine response in schizophrenia, 879
Lavori P, Lohr JB. Whither Vitamin E and Tardive Dyskinesia-ed, 861 See Adler LA
Lawlor B. See Tyrrell J
Lee MS. See Kim YK
Lehmann D. See Saito N
Leibenluft E. See Wehr TA
Lesch K-P. See Sander T
Levin H. See Modahl C
Light GA. See Braff DL
Light GA, Braff DL. The "incredible shrinking" P50 event-related potential, 918
Lim KO
See Lauriello J
See Murphy GM Jr
See Sullivan EV
Lin X-H. See Kitamura N
Linkowski P
See Hubain PP
See Staner L
Lisanby SH, Devanand DP, Prudic J, Pierson D, Nobler MS, Fitzsimons L, Sackeim HA. Prolactin response to electroconvulsive therapy: effects of electrode placement and stimulus dosage, 146
Liston E. See Strober M
Little JT. See Broocks A
Little KY. See López J
Locke J. See Hill SY
Lohr JB. See Lavori P
López J, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin$_{1A}$, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression, 547
Lovestone S. See Holmes C
Lowe CH. See Wehr TA
Lukens E. See Malaspina D
Lydiard RB?
See Johnson MR
See Labbate LA

Maccagno B. See Gianotti L
Mack C. See Broocks A
Madhusoodanan S, Brenner R, Buff D. Mazapertine and hyponatremia, 466-corr
Maes M, Smith RS. Fatty acids, cytokines, and major depression, 313-ed
Magno Zito J. See Carpenter WT Jr
Mahadik JS. See Mahadik SP
Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis, 674
Make BJ. See Hamilos DL
Malaspina D, Harkavy Friedman J, Kaufmann C, Bruder G, Amador X, Strauss D, Clark S, Yale S, Lukens E, Thorning E, Goetz R, Gorman J. Psychobiological heterogeneity of familial and sporadic schizophrenia, 489
Malhotra AK. See Adler CM
Malison RT
See Bowers MB Jr
See Price LH
Mann JJ
See Dyck Flory J
See Sweeney JA, 584
Mann K. See Röschke J
Manor I, Hermesh H, Valevski A, Benjamin Y, Munitz H, Weizman

A. Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis, 288
Manuck SB. See Dyck Flory J
Marangell L. See Parekh PI
Marazitti D. See Johnson MR
Maron M. See Thomas P
Marović A. See Jelovac N
Marsh L. See Sullivan EV
Martin A. See Broocks A
Martucci N. See Bocola V
Maruff P. See Purcell R
Mataki C. See Semba J
Mathalon DH
See Lauriello J
See Sullivan EV
Mattay VS. See Bertolino A
Matthys W. See van Goozen SHM
Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia, 848
McCall WV, Sparks W, Jane J, Rosenquist PB, Colenda CC, Reboussin DM. Variation of ictal electroencephalographic regularity with low-, moderate-, and high-dose stimuli during right unilateral electroconvulsive therapy, 608
McCance-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results, 540
McCarley RW. See Portas CM
McClavert J. See Tyrrell J
McDougle CJ. See Price LH
McElroy SL. See Chang KD
McGue M. See van den Bree MBM
McHale NL. See Mooney JJ
McLaughlin M. See Tyrrell J
McPherson J. See Tyrrell J
Ménard J-F. See Thibaut F
Mendlewicz J
See Hubain PP
See Staner L
Metzger M. See Davis KL
Minichiello MD. See Broocks A
Mita T. See Kitamura N, 254
Mjörndal T. See Spigset O
Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H. Plasma oxytocin levels in autistic children, 270
Moenter JR. See Jin Y
Moffitt TE, Brammer GL, Caspi A, Fawcett JP, Raleigh M, Yuwiler A, Silva P. Whole blood serotonin relates to violence in an epidemiological study, 446
Mohs RC. See Silverman JM
Mooney JJ, Samson JA, McHale NL, Colodzin R, Alpert J, Koutsos M, Schildkraut JJ. Signal transduction by platelet adenylate cyclase: alterations in depressed patients may reflect impairment in the coordinated integration of cellular signals (coincidence detection), 574
Moore P. See Bhatti T
Morris DW. See Warnock JK
Morris M. See Modahl C
Morton WA. See Johnson MR
Motomura E. See Inui K
Mouren-Siméoni M-C. See Bruins-Slot L
Mukherjee S. See Mahadik SP
Muldoon MF. See Dyck Flory J
Munitz H. See Manor I
Munoz RF. See Frederick SL
Murakami N. See Kitamura N
Murphy B. See Peet M
Murphy DGM. See Krasuski JS
Murphy DL. See Broocks A
Murphy GM Jr, Lim KO, Wieneke M, Ellis WG, Forno LS, Hoff AL, Nordahl T. No neuropathologic evidence for an increased frequency of Alzheimer's disease among elderly schizophrenics, 205
Murray RM. See Gutiérrez B
Murry E. See Cassidy F
Myquel M. See Askenazy F

Nagamoto HT. See Freedman R
Naga Venkatesha Murthy PJ. See Rajan I
Nakai H
See Kitamura N
See Yang C-Q
Nakai T. See Kitamura N
Nankai M. See Semba J
Nardali M. See Tutus A
Näsman B. See Rasmuson S
Neale MC. See van den Bree MBM
Neiswanger K. See Hill SY
Nestadt G. See Karayiorgou M
Nestler EJ. See Charney DS
Nishino N
See Kitamura N
See Yang C-Q
Nobler MS. See Lisanby SH
Nomura J. See Inui K
Nordahl T. See Murphy GM Jr
Nutter D. See Hamilos DL

O'Brien C. See Tyrrell J
O'Connor FL. See Delisi SM
Ogura C. See Hirayasu Y
Ohta H. See Hirayasu Y
Okushima R. See Inui K
Olsson T. See Rasmuson S
Ott C. See Rechlin T
Ozaita A. See García-Sevilla JA

Paladini C. See Bocola V
Pantelis C. See Purcell R
Papadimitriou G. See Hubain PP
Parekh PI, Ketter TA, Altshuler L, Frye MA, Callahan A, Marangell L, Post RM. Relationships between thyroid hormone and antidepressant responses to total sleep deprivation in mood disorder patients, 392
Pascual-Marqui RD. See Saito N
Patterson JV. See Jin Y
Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients, 315
Pelc I. See Kornreich C
Pelton GH. See Price LH
Perel JM. See Mavissakalian MR
Perić J. See Jelovac N
Perović D. See Jelovac N
Perrone-Bizzozero NI. See Thompson PM
Peselow E. See Adler LA
Petek M. See Jelovac N
Peters JL. See van Kammen DP
Petit M. See Thibaut F
Petty R. See Kohler C
Pfefferbaum A
See Lauriello J
See Sullivan EV
Pickar D. See Adler CM
Pickens RW. See van den Bree MBM
Pickworth W, Fant R, Goffman A, Henningfield J. Cranial electrostimulation therapy, 468-corr (response)

Pierson D. See Lisanby SH
Pilowsky LS. See Ball S
Pitman RK. See Yehuda R
Poltorak M. See van Kammen DP
Portas CM, Goldstein JM, Shenton ME, Hokama HH, Wible CG, Fischer I, Kikinis R, Donnino R, Jolesz FA, McCarley RW. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging, 649
Post RM. See Parekh PI
Potkin SG. See Jin Y
Powchik P. See Davis KL
Powell JF. See Holmes C
Prentice-Cuntz T. See Röschke J
Pressman A. See Yaffe K
Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR. The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion, 339
Prudic J. See Lisanby SH
Puech AJ. See Askenazy F
Pulver AE. See Karayiorgou M
Purba JS. See Hoogendijk WJG
Purcell R, Maruff P, Kyrios M, Pantelis C. Cognitive deficits in obsessive-compulsive disorder on tests of frontal-striatal function, 348

Rajan I, Naga Venkatesha Murthy PJ, Ramakrishnan AG, Gangadhar BN, Janakiramaiah N. Heart rate variability as an index of cue reactivity in alcoholics, 544
Raleigh M. See Moffitt TE
Ramakrishnan AG. See Rajan I
Ramunni J. See Gianotti L
Rao U. See Strober M
Rapaport M. See Bhatti T
Rapoport SI. See Krasuski JS
Rascle C. See Thomas P
Rasmuson S, Näsman B, Eriksson S, Carlström K, Olsson T. Adrenal responsivity in normal aging and mild to moderate Alzheimer's disease, 401
Ravizza L. See Rocca P
Reboussin DM. See McCall WV
Rechlin T, Weis M, Ott C, Bleichner F, Joraschky P. Alterations of autonomic cardiac control in anorexia nervosa, 358
Red A. See Brown K
Redmond DP. See Hamilos DL
Resnick HS. See Yehuda R
Reus VI. See Frederick SL
Ribeyre J-M. See Thibaut F
Ringo DL. See Lauriello J
Ritchie JC. See Cassidy F
Rocca P, Beoni AM, Eva C, Ferrero P, Zanalda E, Ravizza L. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients, 767
Rommelspacher H. See Sander T
Röschke J, Wagner P, Mann K, Prentice-Cuntz T, Frank C. An analysis of the brain's transfer properties in schizophrenia: amplitude frequency characteristics and evoked potentials during sleep, 503
Rosenberg DR, Keshavan MS. Toward a neurodevelopmental model of obsessive-compulsive disorder, 623
Rosenbloom M. See Lauriello J
Rosenquist PB. See McCall WV
Rosenthal M. See Adler LA
Rossi A. See Johnson MR
Rotrosen J. See Adler LA
Rubinow DR. See Bloch M
Ruĉman R. See Jelovac N
Russ C. See Holmes C

Sackeim HA. See Lisanby SH
Saito N, Kuginuki T, Yagyu T, Kinoshita T, Koenig T, Pascual-Marqui RD, Kochi K, Wackermann J, Lehmann D. Global, regional, and local measures of complexity of multichannel electroencephalography in acute, neuroleptic-naive, first-break schizophrenics, 794
Samson JA. See Mooney JJ
Sander T, Harms H, Dufeu P, Kuhn S, Hoehe M, Lesch K- P, Rommelspacher H, Schmidt LG. Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder, 908
Sandman CA. See Jin Y
Sanger TM. See Tollefson GD
Sauer H. See Schröder J
Schaefer C. See Yaffe K
Schapiro MB. See Krasuski JS
Scheffer R. See Mahadik SP
Scherder EJA, Bouma A, Steen LM. Effects of "isolated" transcutaneous electrical nerve stimulation on memory and affective behavior in patients with probable Alzheimer's disease, 417
Scherrer S. See Schröder J
Schildkraut JJ. See Mooney JJ
Schmaling KB. See Hamilos DL
Schmeidler J. See Yehuda R
Schmider J. See Deuschle M
Schmidt LG. See Sander T
Schmidt PJ. See Bloch M
Schmidtke K, Schorb A, Winkelmann G, Hohagen F. Cognitive frontal lobe dysfunction in obsessive-compulsive disorder, 666
Schorb A. See Schmidtke K
Schuckit M. See Clark CP
Schuff N. See Deicken RF
Schwartz GE. See Bell IR
Schwartz J-C. See Bruins-Slot L
Schweiger U. See Deuschle M
Seeley D. See Yaffe K
Seibyl JP. See Bowers MB Jr
Seifritz E
See Bhatti T
See Hemmeter U
Seiwerth S. See Jelovac N
Semba J, Mataki C, Yamada S, Nankai M, Toru M. Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats, 389
Serper Y. See Cadenhead KS
Servan-Schreiber D, Bruno R, Carter C, Cohen J. Dopamine and the mechanisms of cognition: Part I. A neural network model predicting dopamine effects on selective attention, 713
Servan-Schreiber D, Carter C, Bruno R, Cohen J. Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human subjects performing a selective attention task, 723
Sharpe M. See Young AH
Shaw NA. The effects of

electroconvulsive shock on the primary cortical auditory potential, 595
Shay J. See Peet M
Shenton ME. See Portas CM
Shihabuddin L. See Davis KL
Shimada JM. See Wehr TA
Shirai Y. See Kitamura N
Shirakawa O
See Kitamura N
See Yang C-Q
Schröder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider FJ, Sauer H. D_2 receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with ^{123}I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment, 660
Siever LJ. See Silverman JM
Sikirić P. See Jelovac N
Silva P. See Moffitt TE
Silverman JM, Smith CJ, Guo SL, Mohs RC, Siever LJ, Davis KL. Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders, 97
Silvestri S. See Schröder J
Sim C-B. See Hong C-J
Şimşek A. See Tutus A
Sloan C. See Mavissakalian MR
Smith CJ. See Silverman JM
Smith RS. See Maes M
Smith TL. See Clark CP
Sofuoğlu S. See Tutus A
Sollecito A. See Bocola V
Sower AC. See Thompson PM
Sparks W. See McCall WV
Spiegel-Cohen J. See Davis KL
Spigset O, Allard P, Mjörndal T. Circannual variations in the binding of [^{3}]lysergic acid diethylamide to serotonin$_{2A}$ receptors and of [^{3}]paroxetine to serotonin uptake sites in platelets from healthy volunteers, 774
Stahl S. See Bhatti T
Stålenheim EG, von Knorring L, Wide L. Serum markers of thyroid hormones as biological markers in a Swedish forensic psychiatric population, 755
Standhardt H. See Deuschle M
Staner L. See Hubain PP
Staner L, Van Veeren C, Stefos G, Hubain PP, Linkowski P, Mendlewicz J. Neuroendocrine and clinical characteristics of major depressed patients exhibiting sleep-onset REM, 817
Stanislav SW, Crismon ML, Childs NL. Cerebrospinal fluid monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
Stanton SP. See Chang KD
State M. See Strober M
Steen LM. See Scherder EJA
Steffens DC, Krishnan KRR. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions, 705
Stefos G. See Staner L
Steinhauer SR. See Hill SY
Strakowski SM. See Chang KD
Strauss D. See Malaspina D
Strober M, Rao U, DeAntonio M, Liston E, State M, Amaya-Jackson L, Latz S. Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy, 335
Stroe AE. See Amin F
Ströhle A, Kellner M, Holsboer F, Wiedemann K. Atrial natriuretic hormone decreases endocrine response to a combined dexamethasone-corticotropin-releasing hormone test, 371
Strojwas MH. See Sweeney JA
Su T-P. See Bloch M
Suh KY. See Kim YK
Sullivan EV. See Lauriello J
Sullivan EV, Mathalon DH, Lim KO, Marsh L, Pfefferbaum A. Patterns of regional cortical dysmorphology distinguishing schizophrenia and chronic alcoholism, 118
Sumajstorĉić J. See Jelovac N
Sunderland T. See Broocks A
Svikis DS. See van den Bree MBM
Swaab DF. See Hoogendijk WJG
Swanson CL. See Kohler C
Swarztrauber K, Fujikawa DG. An electroencephalographic study comparing maximum blink rates in schizophrenic and nonschizophrenic psychiatric patients and nonpsychiatric control subjects, 282
Sweeney JA, Strojwas MH, Mann JJ, Thase ME. Prefrontal and cerebellar abnormalities in major depression: evidence from oculomotor studies, 584
Swerdlow NR. See Bakshi VP

Talbott-Green M. See Mavissakalian MR
Tamminga CA. See Lahti AC
Tedeschi G. See Bertolino A
Thase ME. See Sweeney JA
Thibaut F, Ribeyre J-M, Dourmap N, Ménard J- F, Dollfus S, Petit M. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia, 24
Thijssen JHH. See van Goozen SHM
Thomas P, Maron M, Rascle C, Cottencin O, Vaiva G, Goudemand M. Carbamazepine in the treatment of neuroleptic malignant syndrome, 303
Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia, 239
Thorning E. See Malaspina D
Tobin MB. See Bloch M
Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia, 803
Toru M. See Semba J
Tran PV. See Tollefson GD
Träskman-Bendz L. See Westrin Å
Trecco MD. See Bocola V
Tsuneoka Y, Watanabe Y, Goto T, Ichinowatari N. Genomic analysis of schizophrenia by a novel method, 238-corr
Tune L. See Broocks A
Turetsky B, Colbath EA, Gur RE. P300

subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change, 31
Turetsky BI, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology, 84
Turner EH. See Wehr TA
Tutus A, Kuğu N, Sofuoğlu S, Nardali M, Şimşek A, Karaasian F, Gönül AS. Transient frontal hypoperfusion in Tc-99m hexamethyl-propyleneamineoxime single photon emission computed tomography imaging during alcohol withdrawal, 922
Tuyl JP. See Verkes RJ
Tyrrell J, Cosgrave M, Hawi Z, McPherson J, O'Brien C, McClavert J, McLaughlin M, Lawlor B, Gill M. A protective effect of apolipoprotein E e2 allele on dementia in Down's syndrome, 397

Vaiva G. See Thomas P
Valetto MR. See Gianotti L
Valevski A. See Manor I
Vallès V. See Gutiérrez B
van den Berg F. See van Londen L
van den Bree MBM, Johnson EO, Neale MC, Svikis DS, McGue M, Pickens RW. Genetic analysis of diagnostic systems of alcoholism in males, 139
Van der Mast RC. See Verkes RJ
van Engeland H. See van Goozen SHM
van Goozen SHM, Matthys W, Cohen-Kettenis PT, Gispen-de Wied C, Wiegant VM, van Engeland H. Salivary cortisol and cardiovascular activity during stress in oppositional defiant disorder boys and normal controls, 531
van Goozen SHM, Matthys W, Cohen-Kettenis PT, Thijssen JHH, van Engeland H. Adrenal androgens and aggression in conduct disorder prepubertal boys and normal controls, 156
van Kammen DP, Poltorak M, Kelley ME, Yao JK, Gurklis JA, Peters JL, Hemperly JJ, Wright RD, Freed WJ. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia, 680
Van Kempen GMJ. See Verkes RJ
van Londen L, Kerkhof GA, van den Berg F, Goekoop JG, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM, de Wied D. Plasma arginine vasopressin and motor activity in major depression, 196
Van Veeren C. See Staner L
Vargas LA. See Brooks WM
Verbanck P. See Kornreich C
Verkes RJ, Van der Mast RC, Kerkhof AJFM, Fekkes D, Hengeveld M, Tuyl JP, Van Kempen GMJ. Platelet serotonin, monoamine oxidase activity, and [^{3}H]paroxetine binding related to impulsive suicide attempts and borderline personality disorder, 740
Vitrai J. See Carpenter WT Jr
Volavka J. See Carpenter WT Jr
von Knorring L. See Stålenheim EG

Wackermann J. See Saito N
Wagner P. See Röschke J
Wald MC. See Freedman R
Walzer C. See García-Sevilla JA
Ware MR. See Johnson MR
Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy, 464
Watanabe Y. See Tsuneoka Y
Waterhouse L. See Modahl C
Watson SJ. See López J
Weber B. See Deuschle M
Wehr TA, Turner EH, Shimada JM, Lowe CH, Barker C, Leibenluft E. Treatment of a rapidly cycling bipolar patient by using extended bed rest and darkness to stabilize the timing and duration of sleep, 822
Weiler MA. See Lahti AC
Weinberger DR. See Bertolino A
Weiner MW. See Deicken RF
Weis M. See Rechlin T
Weizman A. See Manor I
Westrin Å, Ekman R, Träskman-Bendz L. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder, 734
White T. See Brown K
Whooley M. See Yaffe K
Wible CG. See Portas CM
Wide L. See Stålenheim EG
Wiedemann K. See Ströhle A
Wiegant VM
See van Goozen SHM
See van Londen L
Wieneke M. See Murphy GM Jr
Wingard DL. See Kripke DF
Winkelmann G. See Schmidtke K
Wipprecht G. See Hill SY
Wolyniec PS. See Karayiorgou M
Wright RD. See van Kammen DP
Wuorela M. See Lauerma H

Xu J. See Hill SY

Yaffe K, Ettinger B, Pressman A, Seeley D, Whooley M, Schaefer C, Cummings S. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study
Yagyu T. See Saito N
Yale S. See Malaspina D
Yamada S. See Semba J
Yamamoto H. See Kitamura N
Yang C-Q. See Kitamura N
Yang C-Q, Kitamura N, Nishino N, Shirakawa O, Nakai H. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia, 12
Yang R-K. See Yehuda R
Yao JK. See van Kammen DP
Yehuda R, Resnick HS, Schmeidler J, Yang R-K, Pitman RK. Predictors of cortisol and 3-methoxy-4-hydroxyphenylglycol responses in the acute aftermath of rape, 855
Yeo RA. See Brooks WM
Young AH, Sharpe M, Clements A, Dowling B, Hawton KE, Cowen PJ. Basal activity of the hypothalamic-pituitary-adrenal axis

in patients with the chronic fatigue syndrome (neurasthenia), 236
Yuwiler A. See Moffitt TE

Zabalo MJ. See Andia I
Zanalda E. See Rocca P
Zanarini MC. See Frankenburg FR
Zezza N. See Hill SY
Zhou L. See Deicken RF
Zorrilla EP, Cannon TD, Kessler J, Gur RE. Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia, 887
Zubenko GS. Agitation in dementia, 395-ed
Zumarraga M. See Andia I
Zwinderman KH. See van Londen L

Subject Index to Volume 43

Abstinence
  alcoholics with secondary depression and, 601
  cocaine, homovanillic acid and dopamine transporter, 278
  smoking cessation and, 525
Abstraction
  cognitive frontal lobe dysfunction in obsessive-compulsive disorder and and, 666
Acoustic startle response
  BPC 157 pentadecapeptide and, 511
Active memory search
  cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Adenylate cyclase
  platelet, signal transductionin depression and, 574
Adrenal glands
  Alzheimer's disease and, 401
  androgens, aggression in conduct disorder prepubertal boys and, 156
β-Adrenergic agonists/antagonists
  growth hormone in anorexia nervosa and, 181
Adrenocorticotropic hormone (ACTH)
  adrenal responsivity in Alzheimer's disease, 401
  premenstrual syndrome and, 897
Affective behavior
  "isolated" TENS and, 417
Affective disorders
  carbamazepine for neuroleptic malignant syndrome and, 303
  maximum blink rates in, 282
  neural networks in, 471
  platelet cytosolic calcium responses to serotonin in, 329
Agarose gel electrophoresis
  DRD4 in schizophrenia and, 432
Age
  adrenal responsivity in Alzheimer's disease, 401
  Alzheimer's disease in elderly schizophrenics and, 205
  anorexia nervosa and DRD3 gene, 76
  apolipoprotein E in dementia in Down's syndrome, 397
  apolipoprotein E in depression and Alzheimer's disease, 159
  bipolar disorder in Tourette's syndrome and, 364
  cognitive deficits in obsessive-compulsive disorder and, 348
  cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
  core body temperature in chronic fatigue syndrome, 293
  delta sleep-inducing peptide in suicidality and major depression, 734
  dexamethasone/corticotropin-releasing hormone test and, 762
  dexamethasone suppression test and sleep EEG in depression, 220
  differential effect of haloperidol and clozapine in schizophrenics with or without tardive dyskinesia, 20
  growth hormone in anorexia nervosa and, 181
  5-hydroxytryptamine and anticholinergic effects, 408
  interleukin 2 in schizophrenia and, 701
  middle-latency auditory evoked potentials and, 210
  motor deficits in depression and, 584
  olfactory deficits in schizophrenia and polydypsia, 497
  oxytocin in autism and, 270
  serotonin and violence, 446
  serotonin transporter gene in bipolar affective disorder, 843
  transfer properties in schizophrenia and, 503
Aggression
  posttraumatic, CSF monoamine metabolites and glucose metabolism in, 619
  serotonin and violence, 446
Agitation
  dementia and, 395-ed
Agonists
  signal transduction by platelet adenylate cyclase in depression and, 574
Agoraphobia
  panic disorder with, imipramine for, 848
Alcohol
  disulfiram effects on cocaine use, 540
  serotonin and violence, 446
Alcoholism
  depression in, REM sleep density and, 601
  diagnostic system of alcoholism and genes, 139
  heart rate variability as index of cue reactivity in, 544
  MRI in schizophrenia and alcoholism, 118
  P300 and DRD2 A1 allele in children at alcoholic risk, 40
  platelet indicators of central serotonergic function and, 740
  qEEG in chemically-intolerant women and, 376
  serotonin transporter gene variants in, dissocial personality disorder and, 908
  transient frontal hypoperfusion in Tc-99m hexamethylpropyleneamineoxime SPECT during alcohol withdrawal, 923
  type II, serum levels of thyroid hormones as biological markers and, 755
Alleles
  anorexia nervosa and DRD3 gene, 76
  apolipoprotein E in dementia in Down's syndrome, 397
  apolipoprotein E in depression and Alzheimer's disease, 159
  catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425

© 1998 Society of Biological Psychiatry

0006-3223/98/$19.00
PII S0006-3223(97)00444

DRD4 in schizophrenia and, 432
P300 and DRD2 A1 allele in children at alcoholic risk, 40
serotonin transporter gene in bipolar affective disorder, 843
Allergy
seasonal, chronic fatigue syndrome and, 293
seasonal, core body temperature in chronic fatigue syndrome, 293
Alpha activity
qEEG in chemically-intolerant women and, 376
Alzheimer's disease
adrenal responsivity in, 401
apolipoprotein E in, 159, 397
cortisol in, 401
"isolated" TENS and, 417
medial temporal lobe volumes in, 60
olfactory deficits in schizophrenia and polydypsia, 497
schizophrenia in, 205
Amino acids
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
α-fodrin in schizophrenia and, 254
growth hormone in anorexia nervosa and, 181
impulsivity in anorexia nervosa and, 188
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Amphetamine
dopamine and cognition, 723
haloperidol-induced supersensitivity, BPC 157 pentadecapeptide and, 511
Amplitude
aging effects on middle-latency auditory evoked potentials and, 210
DRD2 A1 allele and children at alcoholic risk, 40
event-related potentials in neuroleptic-naive schizophrenics and, 244
P300 subcomponent abnormalities in schizophrenia and, 31, 84
schizophrenia and, 918, 920, 922 (response)
sensory gating in schizophrenia and, 873
Amplitude-frequency characteristics
transfer properties in schizophrenia and, 503
Amygdala
isotype-specific G protein abnormalities in, schizophrenia and, 12
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Analog markers
whole blood serotonin and, 446
Analysis of variance
aging effects on middle-latency auditory evoked potentials and, 210
clozapine and D_2 receptor occupancy, 79
psychobiological heterogeneity of schizophrenia and, 489
Androgens
adrenal, aggression in conduct disorder prepubertal boys and, 156
adrenal, responsivity in Alzheimer's disease and, 401
premenstrual syndrome and, 897
Androstenedione
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
Animal models
BPC 157 pentadecapeptide and, 511
electroconvulsive shock and primary cortical auditory potential, 595
imidazoline receptors in euthymic bipolar disorder and, 616
isolation rearing-induced deficits in prepulse inhibition and, 436
learned helplessness paradigm in, antidepressantlike effects of chronic nicotine on, 389
Anorexia nervosa
autonomic cardiac control and, 358
D3 dopamine deceptor gene and, 76
growth hormone in, 181
Antabuse
chronic treatment with, intranasal cocaine administration and, 540
Anterior cingulate gyrus
depression in schizophrenia and, 173
P300 subcomponent abnormalities in schizophrenia and, 31
Antibodies
α-fodrin in schizophrenia and, 254
Anticholinergic effects
5-hydroxytryptamine and, 408
Antidepressants
neurobiology of depression and, 547
nicotine and learned helplessness paradigm, 389
signal transduction by platelet adenylate cyclase in depression and, 574
SSRIs and sexual function, 904
tryptophan depletion in depression and, 339
Antioxidants
lipid peroxides at onset of nonaffective psychosis and, 674
Antipsychotics
Alzheimer's disease in elderly schizophrenics and, 205
clozapine and D_2 receptor occupancy, 79
isolation rearing-induced deficits in prepulse inhibition and, 436
leukocyte differentials in schizophrenia and, 887
schizophrenia and, 803
Antisaccade task
motor deficits in depression and, 584
Antisocial behavior
persistent, oppositional defiant disorder boys and, 531
Antisocial personality disorder
serum levels of thyroid hormones as biological markers and, 755
Anxiety
impulsivity in anorexia nervosa and, 188
oppositional defiant disorder boys and, 531

platelet cytosolic calcium responses to serotonin in depression, 329
qEEG in chemically-intolerant women and, 376
schizophrenia and, 803
Anxiety disorders
bipolar disorder in Tourette's syndrome and, 364
immune function and, 458
peripheral benzodiazepine receptor density and, 306
sleep deprivation and, 840
SSRIs and sexual function, 904
Aphenothiazine
carbamazepine for neuroleptic malignant syndrome and, 303
Apnea
sleep, alcoholics with secondary depression and, 601
Apolipoprotein E
Alzheimer's disease and, 159, 397
dementia in Down's syndrome and, 397
depression and, 159
Arginine
growth hormone in anorexia nervosa and, 181
Arginine vasopressin
plasma, in major depression, 196
Arousal
qEEG in chemically-intolerant women and, 376
Artifical neural networks (ANN)
psychopathology and, 471
Association study
anorexia nervosa and DRD3 gene, 76
Assymetrical changes
α-fodrin in schizophrenia and, 254
psychobiological heterogeneity of schizophrenia and, 489
Atenolol
growth hormone in anorexia nervosa and, 181
Atrial natriuretic hormone (ANH)
endocrine response to DEX-CRH test and, 371
Atrophy
hippocampal neuronal dysfunction in schizophrenia and, 483
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Attention
depression in schizophrenia and, 165
dopamine and, 713, 723
qEEG in chemically-intolerant women and, 376
Attentional processing
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Attentional shifting
cognitive deficits in obsessive-compulsive disorder and, 348
Attention-deficit hyperactivity disorder (ADHD)
bipolar disorder in Tourette's syndrome and, 364
"Atypical" psychoses
EEG in functional psychoses and, 69
Auditory evoked potentials
middle-latency, aging and, 210
neuroleptic-naive schizophrenics and, 244
P300 subcomponent abnormalities in schizophrenia and, 84
transfer properties in schizophrenia and, 503
Auditory oddball paradigm
P300 subcomponent abnormalities in schizophrenia and, 31
Auditory paradigms
P300 and DRD2 A1 allele in children at alcoholic risk, 40
Autoimmune hypothesis
interleukin 2 in schizophrenia and, 701
Autonomic cardiac control
anorexia nervosa and, 358
Autonomic nervous system
heart rate variability and cue reactivity in alcoholism, 544
oppositional defiant disorder boys and, 531
Autopsy
α-fodrin in schizophrenia and, 254
Autoradiography
receptor, neurobiology of depression and, 547
Autoreceptors
preclamol in schizophrenia and, 2
Awake/sleep time ratio
arginine vasopressin and motor activity in depression, 196
Awakenings
dexamethasone suppression test and sleep EEG in depression, 220
transfer properties in schizophrenia and, 503

Bal 1 polymorphism
anorexia nervosa and DRD3 gene, 76
Barsky Somatic Symptom Amplification
qEEG in chemically-intolerant women and, 376
Basal ganglia
D_2 receptor in schizophrenia and, 660
motor deficits in depression and, 584
Basal metabolism
core body temperature in chronic fatigue syndrome and, 293
Bed rest
extended, rapid cycling bipolar disorder and, 822
Behavior
BPC 157 pentadecapeptide and, 511
cognitive frontal lobe dysfunction in obsessive-compulsive and, 666
motor deficits in depression and, 584
neural networks and, 471
oppositional defiant disorder boys and, 531
platelet indicators of central serotonergic function and, 740
serotonin and violence, 446
volumetric evaluation of thalamus in schizophrenia and, 649
Benperidol
D_2 receptor in schizophrenia and, 660
Benzodiazepine receptor

peripheral, mRNA in generalized anxiety disorder and, 767
peripheral density, generalized social phobia and, 306
schizophrenia and, 107
Beta blockers
growth hormone in anorexia nervosa and, 181
Between-subjects factors
aging effects on middle-latency auditory evoked potentials and, 210
Bioavailability
major depression and 5-hydroxytryptamine responsivity, 320
Biochemical markers
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Biological markers
P300 and DRD2 A1 allele in children at alcoholic risk, 40
serum levels of thyroid hormones as, 755
whole blood serotonin and, 446
Biological Psychiatry
new leadership for, 1-ed
Bipolar disorder
cortisol reponse to DST and, 747
euthymic, imidazoline receptors in, 616
rapid cycling, extended bed rest and darkness to stabilize sleep patterns in, 822
serotonin transporter gene in, 843
structural imaging in, 705
thyroid function and, 730
Tourette's syndrome in, 364
tryptophan depletion and lithium, 230
Bizarre behavior
volumetric evaluation of thalamus in schizophrenia and, 649
B lymphocytes
anxiety disorders and, 458
Blink rate
maximum, psychiatric disorders and, 282
Blood cells
signal transduction by platelet adenylate cyclase in depression and, 574
Blood pressure
disulfiram effects on cocaine use, 540
Body mass
serotonin and violence, 446
clozapine and body mass change, 520
Body weight
autonomic cardiac control in anorexia nervosa and, 358
clozapine and body mass change, 520
core body temperature in chronic fatigue syndrome and, 293
major depression and 5-hydroxytryptamine responsivity, 320
Borderline personality disorder
platelet indicators of central serotonergic function in, 740
BPC 157 pentadecapeptide
dopamine system and, 511
Brain injury
CSF monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
Brain stem
electroconvulsive shock and primary cortical auditory potential, 595
Brief Psychiatric Rating Scale
clozapine and D_2 receptor occupancy, 79
interleukin 2 in schizophrenia and, 701
P300 subcomponent abnormalities in schizophrenia and, 31, 84
preclamol in schizophrenia and, 2
serum creatine phosphokinase in repeated acute psychosis and, 289
Brief psychotic disorder
EEG in, 69
Brodmann's area 22
α-fodrin in schizophrenia and, 254
Bulimia nervosa
fluoxetine and, 310
impulsivity in anorexia nervosa and, 188
Butyrophenone
carbamazepine for neuroleptic malignant syndrome and, 303

Cambridge Neuropsychological Test Automated Battery
cognitive deficits in obsessive-compulsive disorder and, 348
Captum septum pellucidum
schizophrenia and, 467-corr
Carbamazepine
neuroleptic malignant syndrome and, 303
Carbon dioxide (CO_2) challenge test
antipanic effect of fluoxetine and, 612
Cardiovascular activity
oppositional defiant disorder boys and, 531
Cardiovascular risk factors
clozapine and body mass change, 520
Carpenter's criteria
deficit syndrome of schizophrenia and, 24
Catechol-*O*-methyl-transferase (COMT) gene
schizophrenia susceptibility and, 425
Catecholamines
acute aftermath of rape and, 855
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
deficit and nondeficit schizophrenia, 24
metabolites, reproducibility of plasma levels of in normals, 233
CD19 cells
anxiety disorders and, 458
Cell membranes
red blood cell, depression and, 315
Central inhibitory mechanisms

aging effects on middle-latency auditory evoked potentials and, 210
Central nervous system (CNS)
dopamine and cognition, 723
hypoactivation, qEEG in chemically-intolerant women and, 376
oxytocin in autism and, 270
transfer properties in schizophrenia and, 503
Cerebellar cortex
major depression and, 584
Cerebellar vermis
motor deficits in depression and, 584
Cerebral cortex
aging effects on middle-latency auditory evoked potentials and, 210
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
D_2 receptor in schizophrenia and, 660
electroconvulsive shock and primary cortical auditory potential, 595
α-fodrin in schizophrenia and, 254
MRI in schizophrenia and alcoholism, 118
neurodevelopmental model of obsessive-compulsive disorder and, 623
regionally specific neuronal pathology in schizophrenia and, 641
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
volumetric evaluation of thalamus in schizophrenia and, 649
Cerebral glucose metabolism
depression in schizophrenia and, 173
posttraumatic aggression and, 619
Cerebrospinal fluid (CSF)
monoamine metabolites, glucose metabolism in posttraumatic aggression and, 619
neuronal cell adhesion molecule, schizophrenia and, 680
Chemical cleavage methodology
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Children
at alcoholic risk, P300 and DRD2 A1 allele in, 40
apolipoprotein E in dementia in Down's syndrome and, 397
^{1}H-MRS in childhood schizophrenia and, 263
oxytocin in autism and, 270
Chinese familial schizophrenia
DRD4 in schizophrenia and, 432
Chi-square test
DRD4 in schizophrenia and, 432
p-Chlorophenylpiperazine
scopolamine and, 408
Choice reaction speed
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Choline
hippocampal neuronal dysfunction in schizophrenia and, 483
^{1}H-MRS in childhood schizophrenia and, 263
regionally specific neuronal pathology in chizophrenia and, 641
Cholinergic agonists/antagonists
growth hormone in anorexia nervosa and, 181
Chromosome 22q11
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Chronic fatigue syndrome
core body temperature and, 293
hypothalamic-pituitary-adrenal axis and, 236
Circannual variations
serotonergic parameters and, 774
Circulating lymphocytic surface markers
anxiety disorders and, 458
Classification system
mood disorders and, 705
Climbing behavior
BPC 157 pentadecapeptide and, 511
Cloninger system
diagnostic system of alcoholism and genes, 139
Clozapine
body mass change and, 520
D_2 receptor occupancy and, 79
homovanillic acid and tardive dyskinesia in schizophrenia, 20
schizophrenia and, 879
Cocaine
disulfiram and, 540
withdrawal, homovanillic acid and dopamine transporter, 278
Cognitive frontal lobe dysfunction
obsessive-compulsive disorder and, 666
Cognitive function
dehydroepiandroterone sulfate and, 694
dopamine and, 713, 723
"isolated" TENS and, 417
maximum blink rates in psychiatric patients and, 282
motor deficits in depression and, 584
neural networks and, 471
obsessive-compulsive disorder and, 348
schizophrenia and, 107
Cognitive impairment
mild, medial temporal lobe volumes in, 60
Coincidence detection
signal transduction by platelet adenylate cyclase in depression and, 574
Comorbidity
alcoholics with secondary depression and, 601
anorexia nervosa and DRD3 gene, 76
bipolar disorder in Tourette's syndrome and, 364

cognitive deficits in obsessive-compulsive disorder and, 348
mortality hazard associated with prescription hypnotics and, 687
qEEG in chemically-intolerant women and, 376
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
Compulsions
sertraline discontinuation syndrome in, 929-corr
Compulsive water drinking
fluoxetine and, 310
Computed tomography (CT)
lateral ventricular enlargement in schizophrenia and, 97
Computer simulation models
dopamine and cognition, 713, 723
Conduct disorder
prepubertal boys, adrenal androgens and aggression in, 156
Confusion
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Continuity
sleep, dexamethasone suppression test and sleep EEG in depression, 220
Coordinated integration of cellular signals
signal transduction by platelet adenylate cyclase in depression and, 574
Core body temperature
chronic fatigue syndrome and, 293
Corticosteroids
neurobiology of depression and, 547
withdrawal success and abstinence success in smokers, 525
Corticosterone
neurobiology of depression and, 547
Corticotropin-releasing hormone (CRH)
delta sleep-inducing peptide in suicidality and major depression, 734
depression in Parkinson's disease and, 913
Cortisol
acute aftermath of rape and, 855
adrenal responsivity in Alzheimer's disease, 401
Alzheimer's disease and, 401
atrial natriuretic hormone and DEX-CRH test, 371
delta sleep-inducing peptide in suicidality and major depression, 734
dexamethasone/corticotropin-releasing hormone test and, 762
dexamethasone suppression test and sleep EEG in depression, 220
HPA axis in chronic fatigue syndrome and, 236
major depression and, 401
plasma dexamethasone concentration and manic episodes, 747
premenstrual syndrome and, 897
tryptophan depletion in depression and, 339
withdrawal success and abstinence success in smokers, 525
Court conviction records
serotonin and violence, 446
Covariates
aging effects on middle-latency auditory evoked potentials and, 210
Cox proportional hazards models
mortality hazard associated with prescription hypnotics and, 687
Cranial electrostimulation therapy
"isolated", 417
overview, 468-corr
Creatine
hippocampal neuronal dysfunction in schizophrenia and, 483
^{1}H-MRS in childhood schizophrenia and, 263
regionally specific neuronal pathology in schizophrenia and, 641
Creatine phosphokinase
serum, repeated acute psychosis and, 289
Criminality
serotonin and violence, 446
serum levels of thyroid hormones as biological markers and, 755
Cross-sectional study
aging effects on middle-latency auditory evoked potentials and, 210
Current source density measures
P300 subcomponent abnormalities in schizophrenia and, 31, 84
Cyclothymic disorder
bipolar disorder in Tourette's syndrome and, 364
Cytoarchitecture
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Cytokines
major depression and, 313-ed
Cytoskeletal protein
α-fodrin in schizophrenia and, 254
Cytosol
calcium responses to serotonin in depression and, 329

Darkness
rapid cycling bipolar disorder and, 822
Daytime psychomotor retardation
major depression and, 196
Deficit syndrome
lipid peroxides at onset of nonaffective psychosis, 674
schizophrenia, plasma HVA and MHPH in, 24
Deficit/nondeficit status
P300 subcomponent abnormalities in schizophrenia and, 31, 84
Dehydroepiandrosterone sulfate (DHEAS)
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
dementia and, 401
elderly women and, 694

Déja vu all over again, 781-ed
Delay-dependent visual memory
  cognitive deficits in obsessive-compulsive disorder and, 348
Deletion/insertion polymorphism
  serotonin transporter gene in bipolar affective disorder, 843
Deletions
  catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Delta sleep-inducing peptide
  in suicidality and major depression, 734
Delusions
  ECT in depressed adolescents and, 335
Dementia
  agitation and, 395-ed
  Alzheimer's disease in elderly schizophrenics and, 205
  depression in Parkinson's disease and, 913
  in Down's syndrome, apolipoprotein E and, 397
  medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
  neural networks in, 471
Depot neuroleptic
  clozapine and D_2 receptor occupancy, 79
Depression
  apolipoprotein E in, 159
  arginine vasopressin and motor activity in, 196
  atrial natriuretic hormone and DEX-CRH test in, 371
  core body temperature in chronic fatigue syndrome, 293
  cortisol in, 401
  cytokines and fatty acids-ed, 313
  dehydroepiandroterone sulfate in, 694
  delta sleep-inducing peptide in, 734
  dexamethasone/corticotropin-releasing hormone test in, 762
  dexamethasone suppression test and sleep EEG in, 220
  ECT in adolescents and, 335
  electroconvulsive shock and primary cortical auditory potential in, 595
  history of, 320
  5-hydroxytryptamine responsivity and, 320
  imidazoline receptors in euthymic bipolar disorder and, 616
  microsleep in, 829
  motor activity in, 196
  motor deficits in, 584
  neurobiology of, 547
  nicotine and learned helplessness paradigm, 389
  oculomotor studies in, 584
  omega-3 fatty acids in red blood cell membranes in, 315
  Parkinson's disease in, 913
  partial sleep deprivation in, 829
  platelet cytosolic calcium responses to serotonin in, 329
  prefrontal cortex in, 584
  prolactin response to ECT in, 146
  qEEG in chemically-intolerant women and, 376
  recovery from not associated with normalization of serotonergic function, 320
  in schizophrenia, 165, 173, 803
  secondary, lifetime diagnosis of with alcoholism, 601
  sertraline and GnRH agonist therapy, 464
  sertraline discontinuation syndrome in, 929-corr
  signal transduction by platelet adenylate cyclase in, 574
  sleep EEG in, 220
  sleep-onset REM in, 817
  structural imaging in, 705
  thyroid function in bipolar manic and mixed states, 730
  transfer properties in schizophrenia and, 503
  tryptophan-free amino acid drink challenge effects in, 52
Desipramine
  neurobiology of depression and, 547
Dexamethasone/corticotropin-releasing (DEX/CRH) hormone test
  atrial natiuretic hormone and endocrine response to, 371
  diurnal activity of HPA system and, 762
Dexamethasone suppression test (DST)
  cortisol reponse during manic episodes and, 747
  delta sleep-inducing peptide in suicidality and major depression, 734
  diurnal activity of HPA system and, 762
  sleep EEG in depression and, 220
  withdrawal success and abstinence success in smokers, 525
Diastolic blood pressure
  disulfiram effects on cocaine use, 540
Dichotic listening tasks
  psychobiological heterogeneity of schizophrenia and, 489
Diencephalic seizure propagation
  prolactin response to ECT and, 146
Diet
  serotonin and violence, 446
DiGeorge syndrome
  catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Digital filtering parameter selection
  P50 in schizophrenia and, 921, 922 (response)
Discriminant function analysis
  medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Disinhibition
  platelet indicators of central serotonergic function and, 740
Dissocial personality disorder
  alcoholism with, serotonin transporter gene variants and, 908
  serum levels of thyroid hormones as biological markers and, 755
Disulfiram
  chronic treatment with, intranasal cocaine administration and, 540
Diurnal variation
  serotonin and violence, 446
  HPA system, dexamethasone/corticotropin-releasing hormone test and, 762
Dizygotic twins
  diagnostic system of alcoholism and genes, 139

Docosahexanoic acid (DHA)
depression and, 315
Dopamine
BPC 157 and, 511
cognition and, 713, 723
D_2 receptor, isotype-specific G protein abnormalities in schizophrenia and, 12
D_2 receptor, clozapine and, 79
D_2 receptor, schizophrenia and, 660
DRD2 A1 allele, and P300 in children at alcoholic risk, 40
DRD3 gene, anorexia nervosa and, 76
DRD4 receptor gene, schizophrenia and, 432
neural networks and, 713, 723
neurodevelopmental model of obsessive-compulsive disorder and, 623
partial agonist, preclamol in schizophrenia and, 2
reproducibility of plasma catecholamine metabolites in normals and, 233
transporter, homovanillic acid and cocaine withdrawal, 278
Dorsal processing stream
visual backward masking deficits in schizophrenia and, 132
Dorsolateral prefrontal cortex
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
regionally specific neuronal pathology in schizophrenia and, 641
Dosing
EEG-guided, right unilateral ECT and, 608
Double-blind studies
dopamine and cognition, 723
olanzepine vs. haloperidol, in schizophrenia, 803
prolactin response to ECT and, 146
Down's syndrome
in dementia, apolipoprotein E and, 397
Drug abuse
serotonin and violence, 446
treatment programs, diagnostic system of alcoholism and genes, 139
Drug interaction
disulfiram effects on cocaine use and, 540
Drug-naive state
D_2 receptor in schizophrenia and, 660
Dysmetric visually guided saccades
motor deficits in depression and, 584
Dysphoria
5-hydroxytryptamine and anticholinergic effects, 408

Eating disorders
anorexia nervosa and DRD3 gene, 76
bipolar disorder in Tourette's syndrome and, 364
fluoxetine and, 310
growth hormone in anorexia nervosa and, 181
impulsivity in anorexia nervosa and, 188
Educational status
cognitive deficits in obsessive-compulsive disorder and, 348
80-day washout
differential effect of haloperidol and clozapine in elderly schizophrenics with or without tardive dyskinesia, 20
Elation
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Elderly
Alzheimer's disease in schizophrenia and, 205
dehydroepiandrosterone sulfate and, 694
differential effect of haloperidol and clozapine in schizophrenics with or without tardive dyskinesia, 20
5-hydroxytryptamine and anticholinergic effects, 408
Electroconvulsive shock (ECS)
primary cortical auditory potential and, 595
Electroconvulsive therapy (ECT)
depressed adolescents and, 335
EEG-guided dosing and, 608
prolactin response to, 146
Electrodes
aging effects on middle-latency auditory evoked potentials and, 210
prolactin response to ECT and, 146
Electroencephalogram (EEG)
functional psychoses and, 69
ictal regularity variation, right unilateral ECT and, 608
maximum blink rates in schizophrenia and, 282
multichannel, schizophrenia and, 794
P50 in schizophrenia and, 918
sleep, nonbipolar major depression and, 220
sleep, transfer properties in schizophrenia and, 503
sleep, tryptophan-free amino acid drink challenge effects and, 52
Electrophoresis
DRD4 in schizophrenia and, 432
α-fodrin in schizophrenia and, 254
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Electrophysiology
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Emptiness
chronic feelings of, platelet indicators of central serotonergic function and, 740
Endocrine specificities
anorexia nervosa and DRD3 gene, 76
Endogenous depression
ECT in adolescents and, 335
Endometriosis
sertraline, depression, and GnRH agonist therapy, 464
β-Endorphin
premenstrual syndrome and, 897
Entorhinal cortex
isotype-specific G protein abnormalities in, schizophrenia and, 12

medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Environmental chemical intolerance
qEEG in women and, 376
Environmental influences
diagnostic system of alcoholism and genes, 139
Enzyme-linked immunosorbent assay (ELISA)
interleukin 2 in schizophrenia and, 701
Enzymes
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
signal transduction by platelet adenylate cyclase in depression and, 574
Epidemiological study
serotonin and violence, 446
Epileptiform EEG variants
EEG in functional psychoses and, 69
Episodic memory
5-hydroxytryptamine and anticholinergic effects, 408
ϵ2 allele
apolipoprotein E in dementia in Down's syndrome, 397
apolipoprotein E in depression and Alzheimer's disease, 159
Eriksen task
dopamine and cognition, 713, 723
Escape test
nicotine and learned helplessness paradigm, 389
Estrogen
adrenal responsivity in Alzheimer's disease, 401
Ethnicity
DRD4 in schizophrenia and, 432
interleukin 2 in schizophrenia and, 701
serotonin transporter gene in bipolar affective disorder, 843
Euthymia
tryptophan depletion and lithium, 230
Euthymic bipolar disorder
imidazoline receptors in, 616
Event-related potentials (ERPs)
DRD2 A1 allele and children at alcoholic risk, 40
neuroleptic-naive schizophrenics and, 244
P50 in schizophrenia and, 918
P300 subcomponent abnormalities in schizophrenia and, 31, 84
Evoked potentials
transfer properties in schizophrenia and, 503
Executive function
cognitive deficits in obsessive-compulsive disorder and, 348
Exon I
DRD3 gene, anorexia nervosa and, 76
DRD4 in schizophrenia and, 432
Expiratory reserve volume/vital capacity ratio
antipanic effect of fluoxetine and, 612
Externalizing behavior
oppositional defiant disorder boys and, 531
Extrapyramidal side effects
D_2 receptor in schizophrenia and, 660
Eye movements
motor deficits in depression and, 584
psychobiological heterogeneity of schizophrenia and, 489

Face recognition
"isolated" TENS and, 417
Family history
anorexia nervosa and DRD3 gene, 76
DRD4 in schizophrenia and, 432
lateral ventricular enlargement in schizophrenia and, 97
P300 and DRD2 A1 allele in children at alcoholic risk, 40
P300 subcomponent abnormalities in schizophrenia and, 84
psychobiological heterogeneity of schizophrenia and, 489
qEEG in chemically-intolerant women and, 376
serotonin transporter gene in bipolar affective disorder, 843
Fasting
reproducibility of plasma catecholamine metabolites in normals and, 233
Fatty acids
major depression and, 313-ed
Feighner system
diagnostic system of alcoholism and genes, 139
Fenfluramine
major depression and 5-hydroxytryptamine responsivity, 320
Fever
low-grade, core body temperature in chronic fatigue syndrome and, 293
Filtering
P50 in schizophrenia and, 918, 920, 922 (response)
Fine discrimination
visual backward masking deficits in schizophrenia and, 132
First episode
event-related potentials in neuroleptic-naive schizophrenics, 244
First-degree relatives
psychobiological heterogeneity of schizophrenia and, 489
2-Fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)
depression in schizophrenia and, 173
Fluoxetine
antipanic effect of, 612
bulimia nervosa and compulsive water drinking, 310
Flurazepam
mortality hazard associated with, 687
α-Fodrin
schizophrenia and, 254
Fold stimulation
signal transduction by platelet adenylate cyclase in depression and, 574
Friendliness
tryptophan-free amino acid drink challenge effects on sleep and mood, 52

Frontal assymetry
qEEG in chemically-intolerant women and, 376
Frontal cortex
cognitive deficits in obsessive-compulsive disorder and, 348
D_2 receptor in schizophrenia and, 660
Frontal lobe
depression in schizophrenia and, 165
^{1}H-MRS in childhood schizophrenia and, 263
obsessive-compulsive disorder and, 666
P300 subcomponent abnormalities in schizophrenia and, 31, 84
qEEG in chemically-intolerant women and, 376
regionally specific neuronal pathology in schizophrenia and, 641
Frontostriatal circuitry
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
motor deficits in depression and, 584
neurodevelopmental model of obsessive-compulsive disorder and, 623
Frontotemporal neural network disturbance
P300 subcomponent abnormalities in schizophrenia and, 84
Frustration
oppositional defiant disorder boys and, 531

$GABA_A$/benzodiazepine receptor binding
schizophrenia and, 107
Gastrointestinal tract lesions
BPC 157 pentadecapeptide and, 511
Gating
P50 in schizophrenia and, 918
Gel electrophoresis
α-fodrin in schizophrenia and, 254
DRD4 in schizophrenia and, 432
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Gender
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
adrenal responsivity in Alzheimer's disease, 401
atrial natriuretic hormone and DEX-CRH test, 371
carbamazepine for neuroleptic malignant syndrome and, 303
clozapine and body mass change, 520
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
core body temperature in chronic fatigue syndrome, 293
CSF neuronal cell adhesion molecule in schizophrenia and, 680
dehydroepiandroterone sulfate and, 694
delta sleep-inducing peptide in suicidality and major depression, 734
depression in schizophrenia and, 165
dexamethasone suppression test and sleep EEG in depression, 220
diagnostic system of alcoholism and genes, 139
growth hormone in anorexia nervosa and, 181
heart rate variability and cue reactivity in alcoholism, 544
HPA axis in chronic fatigue syndrome and, 236
interleukin 2 in schizophrenia and, 701
major depression and 5-hydroxytryptamine responsivity, 320
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
mortality hazard associated with prescription hypnotics and, 687
motor deficits in depression and, 584
olfactory deficits in schizophrenia and polydypsia, 497
oppositional defiant disorder boys and, 531
P300 subcomponent abnormalities in schizophrenia and, 31, 84
premenstrual syndrome and, 897
qEEG in chemically-intolerant women and, 376
serotonin and violence, 446
serotonin transporter gene in bipolar affective disorder, 843
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
sertraline, depression, and GnRH agonist therapy, 464
serum creatine phosphokinase in repeated acute psychosis and, 289
thyroid function in bipolar manic and mixed states, 730
transfer properties in schizophrenia and, 503
volumetric evaluation of thalamus in schizophrenia and, 649
Generalized anxiety disorder (GAD)
bipolar disorder in Tourette's syndrome and, 364
peripheral benzodiazepine receptor density and, 306
peripheral benzodiazepine receptor mRNA in lymphocytes in, 767
sleep deprivation and, 840
Generalized seizure activity
electroconvulsive shock and primary cortical auditory potential, 595
Generalized social phobia
immune function and, 458
peripheral benzodiazepine receptor density and, 306
Genetics
anorexia nervosa and DRD3 gene, 76
apolipoprotein E in dementia in Down's syndrome, 397
apolipoprotein E in depression and Alzheimer's disease, 159
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
diagnostic system of alcoholism and genes, 139
DRD4 in schizophrenia and, 432

lateral ventricular enlargement in schizophrenia and, 97
P300 and DRD2 A1 allele in children at alcoholic risk, 40
serotonin transporter gene in bipolar affective disorder, 843
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
Genomic analysis
of schizophrenia by novel method, 238-corr
Genotype
anorexia nervosa and DRD3 gene, 76
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
DRD4 in schizophrenia and, 432
Geriatric Depression Scale-Shortened
dehydroepiandrosterone sulfate in elderly women and, 694
Geriatrics
dehydroepiandrosterone sulfate in elderly women and, 694
Global measures
multichannel electroencephalography and, 794
Glucocorticoids
delta sleep-inducing peptide in suicidality and major depression, 734
receptors, neurobiology of depression and, 547
withdrawal success and abstinence success in smokers, 525
Glucose metabolism
depression in schizophrenia and, 173
posttraumatic aggression and, 619
Glutathione peroxidase
lipid peroxides at onset of nonaffective psychosis, 674
Gonadotropin-releasing hormone (GnRH) agonist therapy
sertraline in treatment of depression associated with, 464
G proteins
imidazoline receptors in euthymic bipolar disorder and, 616
isotypes, schizophrenia and, 12
signal transduction by platelet adenylate cyclase in depression and, 574
Gray matter
MRI in schizophrenia and alcoholism, 118
structural imaging and mood disorders, 705
Growth hormone (GH)
anorexia nervosa and, 181
tryptophan depletion in depression and, 339
Growth hormone-releasing hormone (GHRH)
anorexia nervosa and, 181

Hallucinations
auditory, P300 subcomponent abnormalities in schizophrenia and, 31
volumetric evaluation of thalamus in schizophrenia and, 649
Haloperidol
amphetamine supersensitivity induced by, BPC 157 pentadecapeptide and, 511
homovanillic acid and tardive dyskinesia in schizophrenia, 20
schizophrenia and, 803
Hamilton Depression Rating Scale
alcoholics with secondary depression and, 601
depression in Parkinson's disease and, 913
depression in schizophrenia and, 165, 173
dexamethasone suppression test and sleep EEG in depression, 220
ECT in depressed adolescents and, 335
sertraline, depression, and GnRH agonist therapy, 464
Handedness
volumetric evaluation of thalamus in schizophrenia and, 649
Haplotype reconstruction
serotonin transporter gene in bipolar affective disorder, 843
Head injury
C3F monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
Heart rate variability
autonomic cardiac control in anorexia nervosa and, 358
cue reactivity in alcoholics and, 544
disulfiram effects on cocaine use, 540
Hemispheric laterality assymetry
psychobiological heterogeneity of schizophrenia and, 489
Heritable influences
diagnostic system of alcoholism and genes, 139
Heterogeneity
psychobiological, of familial and sporadic schizophrenia, 489
High-performance liquid chromatography (HPLC)
lipid peroxides at onset of nonaffective psychosis, 674
High-risk factors
P300 and DRD2 A1 allele in children at alcoholic risk, 40
Hippocampus
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
neurobiology of depression and, 547
neuronal dysfunction in schizophrenia and, 483
regionally specific neuronal pathology in schizophrenia and, 641
History of depression
major depression and 5-hydroxytryptamine responsivity, 320
(HLA-DR)-presenting cells
anxiety disorders and, 458
Homovanillic acid (HVA)
CSF monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
in deficit and nondeficit schizophrenia, 24
dopamine transporter during cocaine withdrawal and, 278
metabolites, reproducibility of plasma levels of in normals, 233
in schizophrenia with or without tardive dyskinesia, 20
Homozygosity
DRD4 in schizophrenia and, 432
Hydroxyindoleacetic acid (5-HIAA) 5-
CSF monoamine metabolites and glucose metabolism in

posttraumatic aggression, 619
Hydroxyphenyl)-N-n-propylpiperidine (−)-3-(3-PPP)
schizophrenia and, 2
5-Hydroxytryptamine (5-HT)
anticholinergic effects and, 408
circannual variations in binding and, 774
clozapine and D_2 receptor occupancy, 79
impulsivity in anorexia nervosa and, 188
lithium against mania and, 230
neurodevelopmental model of obsessive-compulsive disorder and, 623
platelet cytosolic calcium responses to serotonin in depression, 329
platelet indicators of central serotonergic function and, 740
tryptophan depletion in depression and, 339
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
whole blood, violence and, 446
5-Hydroxytryptamine$_{1A}$ (5-HT$_{1A}$)
neurobiology of depression and, 547
Hyperactivity
CNS, qEEG in chemically-intolerant women and, 376
dopaminergic, isotype-specific G protein abnormalities in schizophrenia and, 12
sympathoadrenal system, dexamethasone suppression test and sleep EEG in depression, 220
Hyperventilation
chronic, antipanic effect of fluoxetine and, 612
Hypnotics
prescription, mortality hazard associated with, 687
Hypoactivation
CNS, qEEG in chemically-intolerant women and, 376
Hyponatremia
mazapertine and, 466-corr
olfactory deficits in, 497
Hypothalamic paraventricular nucleus
depression in Parkinson's disease and, 913
Hypothalamic-pituitary-adrenal (HPA) axis
chronic fatigue syndrome and, 236
cortisol reponse to DST and, 747
delta sleep-inducing peptide in suicidality and major depression, 734
dexamethasone/corticotropin-releasing hormone test and, 762
neurobiology of depression and, 547
oppositional defiant disorder boys and, 531
smoking cessation and, 525
Hypothalamic-pituitary-adrenocortical system
atrial natriuretic hormone and DEX-CRH test, 371
Hypothalamus
growth hormone in anorexia nervosa and, 181
Hypothesis testing
clozapine and D_2 receptor occupancy, 79
Hypothyroidism
in bipolar manic and mixed states, 730
ICD-10
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
serum levels of thyroid hormones as biological markers and, 755
Illicit drug history
serotonin and violence, 446
Imidazoline
receptors, euthymic biolar disorder and, 616
Imipramine
neurobiology of depression and, 547
for panic disorder with agoraphobia, 848
signal transduction by platelet adenylate cyclase in depression and, 574
Immune function
anxiety disorders and, 458
Immunoblotting
α-fodrin in schizophrenia and, 254
imidazoline receptors in euthymic bipolar disorder and, 616
isotype-specific G protein abnormalities in schizophrenia and, 12
Immunoquantification
α-fodrin in schizophrenia and, 254
Immunoreactivity
plasma, delta sleep-inducing peptide and, 734
Impulse control disorders
bipolar disorder in Tourette's syndrome and, 364
Impulsivity
growth hormone in anorexia nervosa and, 188
platelet indicators of central serotonergic function and, 740
Independent functioning
"isolated" TENS and, 417
Inferior temporal cortex
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Information processing
dopamine and cognition, 713, 723
visual backward masking deficits in schizophrenia and, 132
In situ hybridization
neurobiology of depression and, 547
Insulinlike growth factor 1 (IGF-1)
growth hormone in anorexia nervosa and, 181
Intelligence quotient (IQ)
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
serotonin and violence, 446
Interleukin 2 (IL-2)
Korean schizophrenic patients and, 701
Interpersonal communication
"isolated" TENS and, 417
Intraclass correlation coefficients
reproducibility of plasma catecholamine metabolites in normals and, 233

Intravenous tryptophan infusion
depression and, 339
^{123}I-Iomazenil single photon emission tomography
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
"Isolated" TENS
Alzheimer's disease and, 417
Isolation rearing-induced deficits
in prepulse inhibition, reversal of, 436
Isotype-specific G protein abnormalities
schizophrenia and, 12

Ketamine
healthy volunteers and, 811
Korean schizophrenic patients
interleukin 2 and, 701

Laparoscopy
sertraline, depression, and GnRH agonist therapy, 464
Large neutral amino acids
impulsivity in anorexia nervosa and, 188
Latency
cognitive deficits in obsessive-compulsive disorder and, 348
REM, alcoholics with secondary depression and, 601
REM, tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Lateral cerebral ventricles
enlargement in schizophrenia and, 97
MRI in schizophrenia and alcoholism, 118
Laterality
volumetric evaluation of thalamus in schizophrenia and, 649
Lateralization quotient
psychobiological heterogeneity of schizophrenia and, 489
Leadership
new, for *Biological Psychiatry*, 1
Learned helplessness paradigm
in rats, antidepressantlike effects of chronic nicotine on, 389
Left cerebral hemisphere
isotype-specific G protein abnormalities in, schizophrenia and, 12
Left frontal lobe
^{1}H-MRS in childhood schizophrenia and, 263
Left superior temporal cortex
α-fodrin in schizophrenia and, 254
isotype-specific G protein abnormalities in, schizophrenia and, 12
Left temporal lobe
P300 subcomponent abnormalities in schizophrenia and, 31, 84
Leukocytes
differentials, schizophrenia and, 887
signal transduction by platelet adenylate cyclase in depression and, 574
Limbic system
anorexia nervosa and DRD3 gene, 76
hippocampal neuronal dysfunction in schizophrenia and, 483
isotype-specific G protein abnormalities in, schizophrenia and, 12
neurobiology of depression and, 547
qEEG in chemically-intolerant women and, 376
volumetric evaluation of thalamus in schizophrenia and, 649
Lipid peroxidation products
tardive dyskinesia and, 863
Lipids
tardive dyskinesia and, 863
Lithium
imidazoline receptors in euthymic bipolar disorder and, 616
recently manic patients treated with, tryptophan depletion and, 230
thyroid function in bipolar manic and mixed states, 730
Liver lesions
BPC 157 pentadecapeptide and, 511
Local measures
multichannel electroencephalography and, 794
Long-term memory
"isolated" TENS and, 417
Longitudinal stability
P300 subcomponent abnormalities in schizophrenia and, 31, 84
Longitudinal studies
circannual variations in serotonergic parameters and, 774
alcoholics with secondary depression and, 601
Lymphocytes
immune function and, 458
peripheral benzodiazepine receptor mRNA in, generalized anxiety disorder and, 767
Lysergic acid diethylamide (LSD)
circannual variations in serotonergic parameters and, 774

Magnetic resonance imaging (MRI)
depression in schizophrenia and, 173
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
mood disorders and, 705
in schizophrenia and alcoholism, 118
volumetric evaluation of thalamus in schizophrenia and, 649
Magnetic resonance spectroscopy (MRS)
hippocampal neuronal dysfunction in schizophrenia and, 483
regionally specific neuronal pathology in schizophrenia and, 641
Major depression
arginine vasopressin and motor activity in, 196
core body temperature in chronic fatigue syndrome, 293
cortisol in, 401

cytokines and fatty acids-ed, 313
delta sleep-inducing peptide in, 734
dexamethasone suppression test and sleep EEG in, 220
history of, 320
5-hydroxytryptamine responsivity and, 320
imidazoline receptors in euthymic bipolar disorder and, 616
motor activity in, 196
motor deficits in, 584
oculomotor studies in, 584
peripheral benzodiazepine receptor density and, 306
platelet cytosolic calcium responses to serotonin in, 329
prefrontal cortex in, 584
prolactin response to ECT and, 146
recovery from not associated with normalization of serotonergic function, 320
schizophrenia and, 173
sleep-onset REM in, 817
Malondialdehyde
lipid peroxides at onset of nonaffective psychosis, 674
Mania
cortisol response to DST in, 747
neural networks in, 471
thyroid function and, 730
tryptophan depletion in, 230
Manic-depressive disorder
serotonin transporter gene in bipolar affective disorder, 843
Masking
visual backward masking deficits in schizophrenia and, 132
Maximum blink rates
psychiatric disorders and, 282
Mazapertine
hyponatremia and, 466-corr
McLean Limbic Symptom Checklist
qEEG in chemically-intolerant women and, 376
MDMA
SSRIs and, 929-corr
Mean heart rate
heart rate variability and cue reactivity in alcoholism, 544
Mecamylamine
nicotine and learned helplessness paradigm, 389
Medial temporal lobe volumes
in Alzheimer's disease and mild cognitive impairment, 60
Melancholia
arginine vasopressin and motor activity in depression, 196
Memory
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
5-hydroxytryptamine and anticholinergic effects, 408
"isolated" TENS and, 417
ketamine and, 811
motor deficits in depression and, 584
Menopausal Symptom Index
sertraline, depression, and GnRH agonist therapy, 464
Menstrual cycle
premenstrual syndrome and, 897
Messenger RNA (mRNA)
neurobiology of depression and, 547
peripheral benzodiazepine receptor, generalized anxiety disorder and, 767
Metabolism
basal core body temperature in chronic fatigue syndrome and, 293
brain, depression in schizophrenia and, 173
glucose, posttraumatic aggression and, 619
Methionine
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
(MHPG) 3-Methoxy-4-hydroxyphenylglycol
acute aftermath of rape and, 855
CSF monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
metabolites, reproducibility of plasma levels of in normals, 233
plasma HVA and dopamine transporter during cocaine withdrawal, 278
plasma, in deficit and nondeficit schizophrenia, 24
*O*Methylation
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
3,4-Methylenedioxymethamphetamine (MDMA)
SSRIs and, 929-corr
Mice
BPC 157 pentadecapeptide and, 511
Microdeletions
chromosome 22q11, catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Microsleep
partial sleep deprivation in depression and, 829
Midday sampling
oxytocin in autism and, 270
Middle-latency auditory evoked potentials
aging and, 210
Mineralocorticoid receptors
neurobiology of depression and, 547
Mini-Mental State Examination
dehydroepiandrosterone sulfate in elderly women and, 694
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Mixed states
thyroid function and, 730
Monoamine metabolites
CSF, posttraumatic aggression and, 619
Monoamine oxidase (MAO)
platelet indicators of central serotonergic function and, 740
Monoclonal antibodies
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Mononuclear leukocytes

signal transduction by platelet adenylate cyclase in depression and, 574
Monozygotic twins
diagnostic system of alcoholism and genes, 139
Mood
tryptophan-free amino acid drink challenge effects and, 52
Mood disorders
anorexia nervosa and DRD3 gene, 76
classification system and, 705
EEG in, 69
platelet cytosolic calcium responses to serotonin in, 329
sertraline, depression, and GnRH agonist therapy, 464
structural neuromaging and, 705
tryptophan depletion in depression and, 339
Mood-congruent psychotic features
EEG and, 69
Mood-incongruent psychotic features
EEG and, 69
Morphometric changes
α-fodrin in schizophrenia and, 254
Mortality risk
hazard associated with prescription hypnotics and, 687
Motor activity
depression and, 584
dopamine and cognition, 713, 723
major depression and, 196
preclamol in schizophrenia and, 2
Motor initiation/execution
cognitive deficits in obsessive-compulsive disorder and, 348
Multichannel electroencephalography
schizophrenia and, 794
Multi-impulsive behavior
platelet indicators of central serotonergic function and, 740
Multiple chemical sensitivity
qEEG in chemically-intolerant women and, 376
Multiple linear regression analysis
serum creatine phosphokinase in repeated acute psychosis and, 289
Multiple regression analysis
clozapine and body mass change, 520
Muscle
serum creatine phosphokinase in repeated acute psychosis and, 289
Mutational analysis
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Myoclonus
nocturnal, alcoholics with secondary depression and, 601

N200 amplitude
event-related potentials in neuroleptic-naive schizophrenics, 244
N-Acetylaspartate (NAA)
^{1}H-MRS in childhood schizophrenia and, 263
neuronal dysfunction in schizophrenia and, 483
Na amplitude
aging effects on middle-latency auditory evoked potentials and, 210
Na-Pa amplitude
aging effects on middle-latency auditory evoked potentials and, 210
Natural logarithm
serum creatine phosphokinase in repeated acute psychosis and, 289
Nb-Pb amplitude
aging effects on middle-latency auditory evoked potentials and, 210
Necrosis
hippocampal neuronal dysfunction in schizophrenia and, 483
Negative symptoms
schizophrenia and, 2, 24, 84, 674
Neocortex
motor deficits in depression and, 584
Network dysplasia
neurodevelopmental model of obsessive-compulsive disorder and, 623
Neural generators
multiple, P300 subcomponent abnormalities in schizophrenia and, 84
Neural networks
dopamine and cognition, 713, 723
frontotemporal, P300 subcomponent abnormalities in schizophrenia and, 84
psychopathology and, 471
Neural structural proteins
α-fodrin in schizophrenia and, 254
Neurasthenia
hypothalamic-pituitary-adrenal axis and, 236
Neurobehavioral studies
motor deficits in depression and, 584
Neurobiology
anorexia nervosa and DRD3 gene, 76
depression and, 547
depression in schizophrenia and, 173
psychobiological heterogeneity of schizophrenia and, 489
tryptophan depletion in depression and, 339
Neurochemistry
^{1}H-MRS in childhood schizophrenia and, 263
Neurodevelopmental model
of obsessive-compulsive disorder, 623
Neurodevelopmental theory
^{1}H-MRS in childhood schizophrenia and, 263
Neuroimaging
mood disorders and, 705
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Neuroleptic-naive patients
schizophrenia and, 794

Neuroleptic malignant syndrome
carbamazepine and, 303
serum creatine phosphokinase in repeated acute psychosis and, 289
Neuroleptics
clozapine and D_2 receptor occupancy, 79
D_2 receptor in schizophrenia and, 660
deficit and nondeficit schizophrenia, 24
event-related potentials in neuroleptic-naive schizophrenics, 244
Neuronal cell adhesion molecule
CSF, schizophrenia and, 680
Neurons
hippocampal, schizophrenia and, 483
hypothalamic paraventricular nucleus, depression in Parkinson's disease and, 913
regionally specific pathology, schizophrenia and, 641
somatosensory, BPC 157 pentadecapeptide and, 511
Neuropathology
Alzheimer's disease in elderly schizophrenics and, 205
Neuropeptides
oxytocin in autism and, 270
Neurophysiology
electroconvulsive shock and primary cortical auditory potential, 595
Neuropsychological deficits
depression in schizophrenia and, 165
Neuropsychology
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
''isolated'' TENS and, 417
Neurotransmission
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Neurotransmitters
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Newcastle Scale
dexamethasone suppression test and sleep EEG in depression, 220
Nicotine
chronic, antidepressantlike effects of on learned helplessness paradigm, 389
withdrawal success and abstinence success in smokers, 525
Nighttime motor activity
major depression and, 196
Nla*III* restriction site
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Nonaffective psychosis
plasma lipid peroxides at onset of, 674
Nonbipolar major depression
dexamethasone suppression test and sleep EEG in, 220
Nondeficit form
P300 subcomponent abnormalities in schizophrenia and, 31
Nondeficit status
P300 subcomponent abnormalities in schizophrenia and, 84
Nondeficit-form schizophrenia
plasma HVA and MHPH in, 24
Nonverbal fluency
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Nonverbal short-term memory
''isolated'' TENS and, 417
Norepinephrine
reproducibility of plasma catecholamine metabolites in normals and, 233
Nosologic systems
EEG in functional psychoses and, 69
Nucleus accumbens
isotype-specific G protein abnormalities in, schizophrenia and, 12

Object recognition
visual backward masking deficits in schizophrenia and, 132
Observation scales
''isolated'' TENS and, 417
Obsessive-compulsive disorder (OCD)
cognitive deficits and, 348
cognitive frontal lobe dysfunction and, 666
neurodevelopmental model of, 623
peripheral benzodiazepine receptor density and, 306
Occipital region
MRI in schizophrenia and alcoholism, 118
Occupancy
clozapine and D_2 receptor, 79
Oculomotor studies
major depression and, 584
Oddball paradigm
event-related potentials in neuroleptic-naive schizophrenics, 244
Odors
qEEG in chemically-intolerant women and, 376
Olanzapine
isolation rearing-induced deficits in prepulse inhibition and, 436
schizophrenia and, 803
Olfactory deficits
in schizophrenia and polydypsia, 497
Omega-3 fatty acids
depression and, 315
Ondansetron
scopolamine and, 408
One-way analysis of variance
maximum blink rates in posthoc psychiatric patients and, 282

150-kDa proteins
α-fodrin in schizophrenia and, 254
Oppositional defiant disorder (ODD)
boys, cortisol and cardiovascular activity in, 531
Outcome study
alcoholics with secondary depression and, 601
Overarousal state
dexamethasone suppression test and sleep EEG in depression, 220
Oxidative damage
depression and, 315
Oxytocin
arginine vasopressin and motor activity in depression, 196

P50 amplitude
digital filtering parameter selection and, 922 (response)
schizophrenia and, 918
shrinkage of, 918, 921, 922 (response)
suppression, sensory gating in schizophrenia and, 873
P300 amplitude
DRD2 A1 allele and children at alcoholic risk, 40
event-related potentials in neuroleptic-naive schizophrenics, 244
stability of in schizophrenia, 31
subcomponent abnormalities, schizophrenia and, 84
Pairship group comparison
lateral ventricular enlargement in schizophrenia and, 97
Pancreatic lesions
BPC 157 pentadecapeptide and, 511
Panic disorder
with agoraphobia, imipramine for, 848
bipolar disorder in Tourette's syndrome and, 364
fluoxetine and, 612
immune function and, 458
peripheral benzodiazepine receptor density and, 306
Parahippocampal gyrus
medial temporal lobe volumes in Alzheimer's disease and mild cognitive impairment, 60
Paraventricular nucleus
hypothalamic, depression in Parkinson's disease and, 913
Parents
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
Parietal lobe
MRI in schizophrenia and alcoholism, 118
P300 subcomponent abnormalities in schizophrenia and, 31, 84
qEEG in chemically-intolerant women and, 376
Parkinson's disease
depression in, 913
Paroxetine
circannual variations in serotonergic parameters and, 774
Paroxysmal depolarization shift
electroconvulsive shock and primary cortical auditory potential, 595
Partial dopamine agonist
schizophrenia and, 2
Partial sleep deprivation
depression and, 829
Pattern recognition
cognitive deficits in obsessive-compulsive disorder and, 348
Peak and trough circadian body temperatures
chronic fatigue syndrome and, 293
Pentadecapeptide
novel, dopamine system and, 511
Peripheral benzodiazepine receptor density
generalized social phobia and, 306
Personality disorders
bipolar disorder in Tourette's syndrome and, 364
serum levels of thyroid hormones as biological markers of, 755
Phantom spike and wave
EEG in functional psychoses and, 69
Phenothiazine
carbamazepine for neuroleptic malignant syndrome and, 303
Phenotype
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
P300 subcomponent abnormalities in schizophrenia and, 84
Phlebotomy
season of, serotonin and violence, 446
Phobias
bipolar disorder in Tourette's syndrome and, 364
sleep deprivation and, 840
Phospholipids
depression and, 315
membrane, hippocampal neuronal dysfunction in schizophrenia and, 483
Physical activity
reproducibility of plasma catecholamine metabolites in normals and, 233
Phytohemagglutinin (PHA)
interleukin 2 in schizophrenia and, 701
Pituitary-adrenal hormones
premenstrual syndrome and, 897
Pituitary hormone
prolactin response to ECT and, 146
Planning ability
cognitive deficits in obsessive-compulsive disorder and, 348
Plasma levels
arginine vasopressin, depression and, 196
catecholamine metabolites in normal subjects, reproducibility of, 233
dexamethasone, cortisol response to during manic episodes and, 747
dexamethasone suppression test and sleep EEG in

depression, 220
disulfiram effects on cocaine use, 540
homovanillic acid and dopamine transporter during cocaine withdrawal, 278
homovanillic acid, in schizophrenia with or without tardive dyskinesia, 20
HVA and MHPG, in deficit and nondeficit schizophrenia, 24
immunoreactivity, delta sleep-inducing peptide and, 734
lipid peroxides at onset of nonaffective psychosis, 674
oxytocin in autism and, 270
prolactin, major depression and 5-hydroxytryptamine responsivity, 320
tryptophan, serotonin and violence, 446
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Platelets
adenylate cyclase, depression and, 574
central serotonergic function and, 740
circannual variations in serotonergic parameters and, 774
cytosolic calcium responses in depression, 329
serotonin and violence, 446
Polyacrylamide gels
α-fodrin in schizophrenia and, 254
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Polydypsia
severe, olfactory deficits in, 497
Polymerase chain reaction (PCR)
DRD4 in schizophrenia and, 432
Polymorphisms
anorexia nervosa and DRD3 gene, 76
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
DRD4 in schizophrenia and, 432
serotonin transporter gene in bipolar affective disorder, 843
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
Polysomnography
alcoholics with secondary depression and, 601
dexamethasone suppression test and sleep EEG in depression, 220
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Polyunsaturated fatty acids (PUFAs)
depression and, 315
Positive spikes
EEG in functional psychoses and, 69
Positive symptoms
schizophrenia and, 2, 84, 107
Positron emission tomography (PET)
depression in schizophrenia and, 173
Post hoc tests
maximum blink rates in psychiatric patients and, 282
Postmortem analysis
α-fodrin in schizophrenia and, 254
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Postreceptor measures
signal transduction by platelet adenylate cyclase in depression and, 574
Posttraumatic aggression
CSF monoamine metabolites and glucose metabolism in, 619
Posttraumatic stress disorder (PTSD)
peripheral benzodiazepine receptor density and, 306
rape and, 855
Preclamol
schizophrenia and, 2
Prefrontal association cortex
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Prefrontal cortex
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
isotype-specific G protein abnormalities in, schizophrenia and, 12
major depression and, 584
MRI in schizophrenia and alcoholism, 118
neurodevelopmental model of obsessive-compulsive disorder and, 623
regionally specific neuronal pathology in schizophrenia and, 641
Prefrontal lobe
volumetric evaluation of thalamus in schizophrenia and, 649
Premenstrual syndrome
pituitary-adrenal hormones and testosterone across, 897
Prepubertal boys, conduct disorder in, adrenal androgens and, 156
Prepulse inhibition (PPI)
isolation rearing-induced deficits and, 436
Prescription hypnotics
mortality hazard associated with, 687
Primary cortical auditory potential
electroconvulsive shock and, 595
Probands
male twin, diagnostic system of alcoholism and genes, 139
schizophrenic, DRD4 in schizophrenia and, 432
schizophrenic, lateral ventricular enlargement and, 97
Processing speed
5-hydroxytryptamine and anticholinergic effects, 408
Profile of Mood States
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Prolactin
major depression and 5-hydroxytryptamine responsivity, 320

response to ECT, 146
tryptophan depletion in depression and, 339
Proteolytic fragments
α-fodrin in schizophrenia and, 254
Proton magnetic resonance spectroscopy (^{1}H MRS)
childhood schizophrenia and, 263
neuronal dysfunction in schizophrenia and, 483
regionally specific neuronal pathology in schizophrenia and, 641
Provocation
oppositional defiant disorder boys and, 531
Psychoactive substances
alcoholics with secondary depression and, 601
Psychobiological heterogeneity
of familial and sporadic schizophrenia, 489
Psychomotor retardation
arginine vasopressin and motor activity in depression, 196
Psychopathology
neural networks as models of, 471
Psychopathy
serum levels of thyroid hormones as biological markers and, 755
Psychopathy Checklist-Revised
serum levels of thyroid hormones as biological markers and, 755
Psychosis, 674
DRD4 in schizophrenia and, 432
functional, EEG and, 69
maximum blink rates in, 282
nonaffective, lipid peroxides at onset of, 674
preclamol in, 2
serum creatine phosphokinase in, 289
Psychosis Change Scale
preclamol in schizophrenia and, 2
Psychotherapy
"isolated" TENS and, 417
Psychotic depression
ECT in adolescents and, 335
Pupil size
5-hydroxytryptamine and anticholinergic effects, 408

Quantitative electroencephalogram (qEEG)
differential resting, chemically-intolerant women and, 376
Quiet rest
maximum blink rates in psychiatric patients and, 282

Radio frequency transmitter pill
ingestable, core body temperature in chronic fatigue syndrome and, 293
Radioimmunoassay (RIA)
oxytocin in autism and, 270
Radioligand binding
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
imidazoline receptors in euthymic bipolar disorder and, 616
Rape
acute aftermath of, cortisol and MHPG in, 855
Rapid cycling
bipolar disorder in Tourette's syndrome, 364
extended bed rest and darkness to stabilize sleep patterns in bipolar patient, 822
thyroid function in bipolar manic and mixed states, 730
Rapid eye movement (REM) sleep
alcoholics with secondary depression and, 601
dexamethasone suppression test and sleep EEG in depression, 220
sleep-onset, major depression and, 817
transfer properties in schizophrenia and, 503
tryptophan-free amino acid drink challenge effects and, 52
Rats
BPC 157 pentadecapeptide and, 511
electroconvulsive shock and primary cortical auditory potential, 595
imidazoline receptors in euthymic bipolar disorder and, 616
isolation rearing-induced deficits in prepulse inhibition and, 436
learned helplessness paradigm in, antidepressantlike effects of chronic nicotine on, 389
Read rebreathing test
antipanic effect of fluoxetine and, 612
Receptor autoradiography
neurobiology of depression and, 547
Receptors
anorexia nervosa and DRD3 gene, 76
circannual variations in serotonergic parameters, 774
D_2 dopamine, schizophrenia and, 660
dopamine D_2, 79
DRD2 A1 dopamine, and P300 in children at alcoholic risk, 40
euthymic bipolar disorder and, 616
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
hippocampus in neurobiology of depression, 547
isotype-specific G protein abnormalities in schizophrenia and, 12
nicotine and learned helplessness paradigm, 389
peripheral benzodiazepine receptor density in social phobia, 306
peripheral benzodiazepine receptor mRNA in lymphocytes in generalized anxiety disorder, 767
preclamol in schizophrenia and, 2
tryptophan depletion in depression and, 339
withdrawal success and abstinence success in smokers, 525
Red blood cells
lipid peroxides at onset of nonaffective psychosis, 674
membranes in depression, omega-3 fatty acid depletion and, 315
Regional brain volumes
clozapine in schizophrenia and, 879
Regional cortical dysmorphology
distinguishing schizophrenia and alcoholism, 118

Regional measures
multichannel electroencephalography and, 794
Regional pathology
P300 subcomponent abnormalities in schizophrenia and, 84
Regression analysis
dexamethasone suppression test and sleep EEG in depression, 220
Regularity
seizure, EEG-guided dosing and, 608
Reinforcement behavior
anorexia nervosa and DRD3 gene, 76
Relapse
three-month, alcoholics with secondary depression and, 601
Relatives
P300 and DRD2 A1 allele in children at alcoholic risk, 40
psychobiological heterogeneity of schizophrenia and, 489
Repeated acute psychosis
serum creatine phosphokinase in, 289
Reproducibility
of plasma catecholamine metabolites in normal subjects, 233
Respiratory symptoms
antipanic effect of fluoxetine and, 612
Response inhibition
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
neurodevelopmental model of obsessive-compulsive disorder and, 623
Restored weight
autonomic cardiac control in anorexia nervosa and, 358
Restriction fragment length polymorphisms (RFLPs)
P300 and DRD2 A1 allele in children at alcoholic risk, 40
Reward behavior
anorexia nervosa and DRD3 gene, 76
Rhabdomyolysis
serum creatine phosphokinase in repeated acute psychosis and, 289
Right parietal lobe
P300 subcomponent abnormalities in schizophrenia and, 31
Right unilateral electroconvulsive therapy (RUL ECT)
EEG-guided dosing and, 608
Risk factors
acute aftermath of rape and, 855
apolipoprotein E in depression and Alzheimer's disease, 159
cardiovascular, clozapine and body mass change, 520
mortality hazard associated with prescription hypnotics and, 687
serotonin transporter gene in bipolar affective disorder, 843
R-R intervals
heart rate variability and cue reactivity in alcoholism, 544

Saccades
motor deficits in depression and, 584
Salbutamol
growth hormone in anorexia nervosa and, 181
Saline
atrial natriuretic hormone and DEX-CRH test, 371
Salivary levels
cortisol, oppositional defiant disorder boys and, 531
HPA axis in chronic fatigue syndrome and, 236
Same-sex cotwins
diagnostic system of alcoholism and genes, 139
Scalp
aging effects on middle-latency auditory evoked potentials and, 210
transfer properties in schizophrenia and, 503
Schizoaffective disorder
bipolar disorder in Tourette's syndrome and, 364
carbamazepine for neuroleptic malignant syndrome and, 303
EEG in, 69
lateral ventricular enlargement in schizophrenia and, 97
Schizophrenia
Alzheimer's disease in, 205
captum septum pellucidum in, 467-corr
catechol-*O*-methyl-transferase gene in susceptibility to, 425
clozapine in, 879
cognitive function in, 107
CSF neuronal cell adhesion molecule in, 680
D_2 dopamine receptor in, 660
deficit, plasma HVA and MHPG in, 24
depression in, 165, 173
EEG and maximum blink rates in, 282
EEG in, 69
event-related potentials in neuroleptic-naive schizophrenics, 244
familial, 489
first-break, 794
α-fodrin in, 254
$GABA_A$/benzodiazepine receptor binding in, 107
genomic analysis of schizophrenia by novel method, 238-corr
haloperidol in, 803
hippocampal neuronal dysfunction in schizophrenia and, 483
−-3-(3-hydroxyphenyl)-N-n-propylpiperidine in, 2
interleukin 2 in, 701
isolation rearing-induced deficits in prepulse inhibition and, 436
lateral ventricular enlargement in, 97
leukocyte differentials in, 887
lipid peroxides at onset of nonaffective psychosis, 674
maximum blink rates in, 282
MRI in schizophrenia and alcoholism, 118
^{1}H-MRS in childhood schizophrenia and, 263
multichannel EEG in, 794
neural networks in, 471
neurodevelopmental theory for, 263
nondeficit, plasma HVA and MHPG in, 24

olanzapine in, 803
olfactory deficits in, 497
P50 in, 873, 918
P300 in, 31, 84
partial dopamine agonist in, 2
poor-outcome, 783
preclamol in, 2
psychobiological heterogeneity of, 489
regional brain volumes in, 879
regionally specific neuronal pathology in, 641
sensory gating in, 873
serum creatine phosphokinase in, 289
SNAP-25 protein in, 239
sporadic, 489
transfer properties in, 503
ventricular enlargement in, 783
visual backward masking deficits in, 132
volumetric evaluation of thalamus in, 649
Schizophrenia spectrum disorders
^{1}H-MRS in childhood schizophrenia and, 263
Schizophreniform disorder
EEG in, 69
lipid peroxides at onset of nonaffective psychosis, 674
Schizotypal personality disorder
lateral ventricular enlargement in schizophrenia and, 97
Scopolamine
p-chlorophenylpiperazine and, 408
ondansetron and, 408
Seasonality of recurrence
bipolar disorder in Tourette's syndrome and, 364
Second-degree relatives
psychobiological heterogeneity of schizophrenia and, 489
Secondary depression
alcoholism and, 601
Seizures
electroconvulsive shock and primary cortical auditory potential, 595
prolactin response to ECT and, 146
regularity, EEG-guided dosing and, 608
Selective attention
dopamine and, 713, 723
Selective serotonin reuptake inhibitors (SSRIs)
MDMA and, 928-corr
platelet cytosolic calcium responses to serotonin in depression, 329
sertraline, depression, and GnRH agonist therapy, 464
sexual function in anxiety disorders and, 904
Self-injurious behavior
bipolar disorder in Tourette's syndrome and, 364
Self-rated functional impairment
5-hydroxytryptamine and anticholinergic effects, 408
Self-reality
altered, 5-hydroxytryptamine and anticholinergic effects, 408
Semantic memory
ketamine and, 811
Sensation seeking
platelet indicators of central serotonergic function and, 740
Sensorimotor cortex
volumetric evaluation of thalamus in schizophrenia and, 649
Sensorimotor gating
isolation rearing-induced deficits in prepulse inhibition and, 436
schizophrenia and, 873
Sequence variants
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Seroquel
isolation rearing-induced deficits in prepulse inhibition and, 436
Serotonin
circannual variations in binding and, 774
clozapine and D_2 receptor occupancy, 79
lithium against mania and, 230
neurodevelopmental model of obsessive-compulsive disorder and, 623
platelet cytosolic calcium responses to serotonin in depression, 329
platelet indicators of central serotonergic function and, 740
transporter gene, bipolar affective disorder and, 843
transporter gene variants, in alcoholics with dissocial personality disorder, 908
tryptophan depletion in depression and, 339
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
whole blood, impulsivity in anorexia nervosa and, 188
whole blood, violence and, 446
Serotonin$_{1A}$
neurobiology of depression and, 547
Serotonin/violence hypothesis
epidemiological level and, 446
Sertraline
depression and GnRH agonist therapy, 464
Sertraline discontinuation syndrome
presenting with severe depression and compulsions, 929-corr
Serum levels
adrenal responsivity in Alzheimer's disease, 401
creatine phosphokinase in repeated acute psychosis and, 289
thyroid hormones, as biological markers, 755
tryptophan depletion and lithium, 230
tryptophan depletion in depression and, 339
Set-shifting
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Sexual function
anxiety disorders and, 904
Sham simulation

"isolated" TENS and, 417
Short-term memory
cognitive deficits in obsessive-compulsive disorder and, 348
Siblings
of schizophrenics, lateral ventricular enlargement and, 97
Signal-to-noise ratio
P50 in schizophrenia and, 918
signal transduction by platelet adenylate cyclase in depression and, 574
Signal transduction
platelet adenylate cyclase in depression and, 574
Single-photon emission tomography (SPECT)
D_2 receptor in schizophrenia and, 660
$GABA_A$/benzodiazepine receptor binding in schizophrenia and, 107
plasma HVA and dopamine transporter during cocaine withdrawal, 278
transient frontal hypoperfusion in, alcohol withdrawal and, 923
Single-strand conformation polymorphism
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
SLC6A4 gene
alcoholics with dissocial personality and disorder, 908
bipolar affective disorder and, 929
Sleep
alcoholics with secondary depression and, 601
arginine vasopressin and motor activity in depression, 196
deprivation, in social phobia and generalized anxiety disorder, 840
EEG, dexamethasone suppression test in depression and, 220
EEG, transfer properties in schizophrenia and, 503
EEG, tryptophan-free amino acid drink challenge effects and, 52
REM, tryptophan-free amino acid drink challenge effects and, 52
timing and duration, rapid cycling bipolar disorder and, 822
Sleeping pills
prescription, mortality hazards associated with, 687
Sleep-onset-REM
major depression and, 817
Slow-wave sleep
dexamethasone suppression test and sleep EEG in depression, 220
transfer properties in schizophrenia and, 503
Small sharp spikes
EEG in functional psychoses and, 69
SMI-81 monoclonal antibodies
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Smoking
cessation, hypothalamic-pituitary-adrenal axis and, 525
cessation, nicotine and learned helplessness paradigm, 389
decrease in, clozapine and body mass change, 520
reproducibility of plasma catecholamine metabolites in normals and, 233
Smooth pursuit eye movement
psychobiological heterogeneity of schizophrenia and, 489
SNAP-25 synaptosomal associated protein
schizophrenia and, 239
Social deficits
oxytocin in autism and, 270
Social drinkers
heart rate variability and cue reactivity in alcoholism, 544
Social phobia
immune function and, 458
peripheral benzodiazepine receptor density and, 306
sleep deprivation and, 840
Socioeconomic status
major depression and 5-hydroxytryptamine responsivity, 320
serotonin and violence, 446
volumetric evaluation of thalamus in schizophrenia and, 649
Sodium dodecyl sulfate (SDS) buffer
α-fodrin in schizophrenia and, 254
Sodium dodecyl sulfate (SDS) buffer
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Soft signs
neurological, D_2 receptor in schizophrenia and, 660
Somatization
qEEG in chemically-intolerant women and, 376
Somatosensory neurons
BPC 157 pentadecapeptide and, 511
Somatostatin
growth hormone in anorexia nervosa and, 181
Spatial delayed response task
motor deficits in depression and, 584
Spatial recognition
cognitive deficits in obsessive-compulsive disorder and, 348
Spatial relationships
visual backward masking deficits in schizophrenia and, 132
Spatial working memory
cognitive deficits in obsessive-compulsive disorder and, 348
Spectral power analysis
autonomic cardiac control in anorexia nervosa and, 358
Spontaneity
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Sporadic illness
psychobiological heterogeneity of schizophrenia and, 489
Standing posture
autonomic cardiac control in anorexia nervosa and, 358
Startle response
isolation rearing-induced deficits in prepulse inhibition and, 436
Stepwise multiple-regression analysis

clozapine and body mass change, 520
Stereotypy
amphetamine, BPC 157 pentadecapeptide and, 511
Stress
immune function and, 458
lipid peroxides at onset of nonaffective psychosis, 674
neurobiology of depression and, 547
oppositional defiant disorder boys and, 531
qEEG in chemically-intolerant women and, 376
Striatum
cognitive deficits in obsessive-compulsive disorder and, 348
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
motor deficits in depression and, 584
neurodevelopmental model of obsessive-compulsive disorder and, 623
plasma HVA and dopamine transporter during cocaine withdrawal, 278
Structural neuroimaging
mood disorders and, 705
Subcomponent abnormalities
P300, schizophrenia and, 84
Subcortical dysfunction
cognitive deficits in obsessive-compulsive disorder and, 348
Subcortical locations
electroconvulsive shock and primary cortical auditory potential, 595
Subcortical regions
regionally specific neuronal pathology in schizophrenia and, 641
Subcortical systems
aging effects on middle-latency auditory evoked potentials and, 210
Subnormal body temperature
chronic fatigue syndrome and, 293
Subtype-specific differences
P300 subcomponent abnormalities in schizophrenia and, 84
Suicidality
delta sleep-inducing peptide in, 734
platelet indicators of central serotonergic function and, 740
serotonin and violence, 446
Suicide victims
neurobiology of depression and, 547
Sulci
cortical, MRI in schizophrenia and alcoholism, 118
Superior temporal cortex
α-fodrin in schizophrenia and, 254
Supine posture
autonomic cardiac control in anorexia nervosa and, 358
Suprathreshold
EEG-guided dosing and, 608
Sustained visual channels
schizophrenia and, 132
Swedish forensic psychiatric population
serum levels of thyroid hormones as biological markers and, 755
Sympathetic nervous system
oppositional defiant disorder boys and, 531
Sympathoadrenal system hyperactivity
dexamethasone suppression test and sleep EEG in depression, 220
Symptom Checklist 90
qEEG in chemically-intolerant women and, 376
Synaptosomal-associated protein
schizophrenia and, 239
Systolic blood pressure
disulfiram effects on cocaine use, 540

Tachyphylaxis
preclamol in schizophrenia and, 2
Tactile stimulation
''isolated'' TENS and, 417
Taq1A D2 receptor
P300 and DRD2 A1 allele in children at alcoholic risk, 40
Tardive dyskinesia
in elderly schizophrenics, differential effect of haloperidol and clozapine on, 20
lipid peroxidation products and, 863
lipids and, 863
vitamin E and, 861-ed, 863, 868
Target letter identification
visual backward masking deficits in schizophrenia and, 132
Tc-99m hexamethylpropyleneamineoxime SPECT
transient frontal hypoperfusion in, alcohol withdrawal and, 923
Teachers
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
Temazepam
mortality hazard associated with, 687
Temporal cortex
electroconvulsive shock and primary cortical auditory potential, 595
Temporal lobe
depression in schizophrenia and, 173
α-fodrin in schizophrenia and, 254
MRI in schizophrenia and alcoholism, 118
P300 subcomponent abnormalities in schizophrenia and, 31, 84
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Tension
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Testosterone
adrenal androgens and aggression in conduct disorder prepubertal boys, 156
premenstrual syndrome and, 897

Thalamus
electroconvulsive shock and primary cortical auditory potential, 595
volumetric evaluation of thalamus in, 649
Theta resonance
transfer properties in schizophrenia and, 503
Thiobarbituric acid reactive substances
lipid peroxides at onset of nonaffective psychosis, 674
Third cerebral ventricle
MRI in schizophrenia and alcoholism, 118
Thought disorder
ketamine and, 811
volumetric evaluation of thalamus in schizophrenia and, 649
Three-month relapse
alcoholics with secondary depression and, 601
Threshold modeling
diagnostic system of alcoholism and genes, 139
Thyroid function
in bipolar manic and mixed states, 730
core body temperature in chronic fatigue syndrome and, 293
Thyroid hormones
serum levels of, as biological markers, 755
Thyroid-stimulating hormone (TSH)
in bipolar manic and mixed states, 730
Thyroxine (T_4)
serum levels of, as biological marker, 755
thyroid function in bipolar manic and mixed states, 730
Tics
bipolar disorder in Tourette's syndrome and, 364
Time and frequency domain parameters
heart rate variability and cue reactivity in alcoholism, 544
Tobacco
serotonin and violence, 446
Tone tasks
psychobiological heterogeneity of schizophrenia and, 489
Tourette's syndrome
bipolar disorder in, 364
Transcutaneous electrical nerve stimulation (TENS)
"isolated", 417
overview, 468-corr
Transfer properties
schizophrenia and, 503
Transient frontal hypoperfusion
in Tc-99m hexamethylpropyleneamineoxime SPECT, alcohol withdrawal and, 922
Transient visual channels
vs sustained visual channels, schizophrenia and, 132
Transporter
dopamine, homovanillic acid and cocaine withdrawal, 278
Transporter gene
serotonin, in alcoholics with dissocial personality disorder, 908
serotonin, bipolar affective disorder and, 843
Traumatic brain injury
CSF monoamine metabolites and glucose metabolism in posttraumatic aggression, 619
Triazolam
mortality hazard associated with, 687
Tridimensional Personality Questionnaire
serotonin transporter gene variants in alcoholics with dissocial personality disorder, 908
Triiodothyronine (T_3)
in bipolar manic and mixed states, 730
serum levels of, as biological marker, 755
Tryptophan
depletion, depression and, 339
depletion, in recently manic patients treated with lithium, 230
impulsivity in anorexia nervosa and, 188
plasma level, serotonin and violence, 446
Tryptophan-free amino acid drink (TFD)
challenge effects on sleep and mood, 52
Twelve-nucleotide repeat polymorphism
DRD4 in schizophrenia and, 432
Twentyfour 24-hour profiles
core body temperature in, 293
dexamethasone/corticotropin-releasing hormone test and, 762
Twin study
diagnostic system of alcoholism and genes, 139
Two-way analyses of variance
aging effects on middle-latency auditory evoked potentials and, 210

Unipolar depression
imidazoline receptors in euthymic bipolar disorder and, 616
structural imaging in, 705
Univariate structural equation modeling
diagnostic system of alcoholism and genes, 139
University of Pennsylvania Smell Identification Test
olfactory deficits in schizophrenia and polydypsia, 497
Up-regulation
D_2 receptor in schizophrenia and, 660
imidazoline receptors in euthymic bipolar disorder and, 616
Urinary levels
HPA axis in chronic fatigue syndrome and, 236

Valine
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Vegetative depressive symptoms
bipolar disorder in Tourette's syndrome and, 364
Velocardiofacial syndrome
catechol-*O*-methyl-transferase gene and schizophrenia susceptibility, 425
Ventral prefrontal cortex
neurodevelopmental model of obsessive-compulsive disorder and, 623
Ventral processing stream

visual backward masking deficits in schizophrenia and, 132
Ventricles
cerebral, volumetric evaluation of thalamus in schizophrenia and, 649
Ventricular enlargement
lateral, schizophrenia and, 97
poor-outcome schizophrenia and, 783
Verbal fluency
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
"isolated" TENS and, 417
Vesicular protein
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
Vigilance
depression in schizophrenia and, 165
Vigor
tryptophan-free amino acid drink challenge effects on sleep and mood, 52
Visual backward masking deficits
schizophrenia and, 132
Visual fixation
motor deficits in depression and, 584
Visual memory
"isolated" TENS and, 417
Visual paradigms
P300 and DRD2 A1 allele in children at alcoholic risk, 40
Vitamin E
tardive dyskinesia and, 861-ed, 863, 868

Waist-hip ratios
clozapine and body mass change, 520
Wakefulness
arginine vasopressin and motor activity in depression, 196
Water bath calibration
core body temperature in chronic fatigue syndrome and, 293
Water drinking
compulsive, fluoxetine and, 310
Water intoxication
olfactory deficits in, 497
Weaning
isolation rearing-induced deficits in prepulse inhibition and, 436
Weight gain
clozapine and body mass change, 520
Weight sorting
cognitive frontal lobe dysfunction in obsessive-compulsive disorder and, 666
Western blot analysis
CSF neuronal cell adhesion molecule in schizophrenia and, 680
Western blotting analysis
SNAP-25 synaptosomal associated protein in schizophrenia and, 239
White matter
MRI in schizophrenia and alcoholism, 118
structural imaging and mood disorders, 705
Whole blood serotonin
violence and, 446
Whole blood serotonin content
impulsivity in anorexia nervosa and, 188
Withdrawal
alcohol, transient frontal hypoperfusion in Tc-99m hexamethylpropyleneamineoxime SPECT during, 922
alcoholics with secondary depression and, 601
cocaine, homovanillic acid and dopamine transporter, 278
distress, smoking cessation and, 525
Within-sibship analysis
lateral ventricular enlargement in schizophrenia and, 97
Within-subject factors
aging effects on middle-latency auditory evoked potentials and, 210
Word fluency
"isolated" TENS and, 417
Word tasks
psychobiological heterogeneity of schizophrenia and, 489
Working memory
ketamine and, 811
motor deficits in depression and, 584

Zimelidine
neurobiology of depression and, 547